<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02293837</url>
  </required_header>
  <id_info>
    <org_study_id>DAIT ITN058AI</org_study_id>
    <nct_id>NCT02293837</nct_id>
  </id_info>
  <brief_title>Tocilizumab (TCZ) in New-onset Type 1 Diabetes</brief_title>
  <acronym>EXTEND</acronym>
  <official_title>Preserving Beta-Cell Function With Tocilizumab in New-onset Type 1 Diabetes (ITN058AI)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Immune Tolerance Network (ITN)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>PPD</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rho Federal Systems Division, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Type 1 diabetes mellitus (T1DM) is an autoimmune disease. Based on previous research, study&#xD;
      doctors think that giving medicines to affect the immune system soon after diabetes is&#xD;
      diagnosed may stop, delay or decrease the destruction of beta cells, resulting in better&#xD;
      glucose control.&#xD;
&#xD;
      Researchers believe that tocilizumab could have some effect on the cells in the immune system&#xD;
      that are thought to be involved in the development of type 1 diabetes. This study will test&#xD;
      whether tocilizumab can help preserve or delay destruction of remaining beta cells in people&#xD;
      recently diagnosed type 1 diabetes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Staggered enrollment is planned for this trial.&#xD;
&#xD;
      Prior to initiating the study in the pediatric age group (6-17 years old), 30-99 eligible&#xD;
      adults (ages 18-45 years) will be randomized 2:1 to tocilizumab or placebo, respectively.&#xD;
      Once the first thirty adult participants have completed 12 weeks of treatment, the FDA and&#xD;
      Data and Safety Monitoring Board (DSMB) will review available data (e.g., interim analysis)&#xD;
      to weigh potential risks and benefits before opening the trial to pediatric participants.&#xD;
&#xD;
      As of â‰¥ May 15, 2017: Study enrollment limited to participants ages 6 to 17 years inclusive.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 12, 2015</start_date>
  <completion_date type="Actual">August 31, 2020</completion_date>
  <primary_completion_date type="Actual">July 10, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in 2-Hour C-peptide Mean Area Under the Curve (mAUC) in Pediatric Participants</measure>
    <time_frame>Baseline (Pre-treatment) to Week 52</time_frame>
    <description>C-peptide is a substance released by the pancreas into the bloodstream in equal amounts to insulin and reflects how much insulin pancreatic beta cells are making. The standardized MMTT evaluates whether beta cells are producing endogenous insulin. The MMTT was performed in the morning and blood samples for C-peptide collected at baseline (pre-meal) and 15, 30, 60, 90, 120, 150, 180, 210, and 240 minutes post-meal. C-peptide mAUC was calculated using the trapezoidal rule over the 2-hour time period. Larger numbers are preferable (better) in these mAUC results: more insulin being produced reflects less severe disease. C-peptide levels in the serum (e.g., mAUC following a standardized MMTT) compared to control group at 1 year post treatment initiation for the evaluation of investigational products intended to preserve endogenous beta-cell function in T1DM trials is recognized by the Center for Drug Evaluation and Research (CDER) at the FDA as a valid efficacy endpoint.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 2-Hour C-peptide Mean Area Under the Curve (mAUC)</measure>
    <time_frame>Baseline (Pre-treatment) to Weeks 24, 52, and 104</time_frame>
    <description>C-peptide is a substance released by the pancreas into the bloodstream in equal amounts to insulin and reflects how much insulin pancreatic beta cells are making. The standardized MMTT evaluates whether beta cells are producing endogenous insulin. The MMTT was performed in the morning and blood samples for C-peptide collected at baseline (pre-meal) and 15, 30, 60, 90, 120, 150, 180, 210, and 240 minutes post-meal. C-peptide mAUC was calculated using the trapezoidal rule over the 2-hour time period. Larger numbers are preferable (better) in these mAUC results: more insulin being produced reflects less severe disease. C-peptide levels in the serum (e.g., mAUC following a standardized MMTT) compared to control group at 1 year post treatment initiation for the evaluation of investigational products intended to preserve endogenous beta-cell function in T1DM trials is recognized by the Center for Drug Evaluation and Research (CDER) at the FDA as a valid efficacy endpoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2-Hour C-peptide Mean Area Under the Curve (mAUC), Mixed Model</measure>
    <time_frame>Baseline (Pre-treatment), Weeks 12, 24, 39, 52, 78, and 104</time_frame>
    <description>C-peptide is a substance released by the pancreas into the bloodstream in equal amounts to insulin and reflects how much insulin pancreatic beta cells are making. The standardized MMTT evaluates whether beta cells are producing endogenous insulin. The MMTT was performed in the morning and blood samples for C-peptide collected at baseline (pre-meal) and 15, 30, 60, 90, 120, 150, 180, 210, and 240 minutes post-meal. C-peptide mAUC was calculated using the trapezoidal rule over the 2-hour time period. Larger numbers are preferable (better) in these mAUC results: more insulin being produced reflects less severe disease. C-peptide levels in the serum (e.g., mAUC following a standardized MMTT) compared to control group at 1 year post treatment initiation for the evaluation of investigational products intended to preserve endogenous beta-cell function in T1DM trials is recognized by the Center for Drug Evaluation and Research (CDER) at the FDA as a valid efficacy endpoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 4-Hour C-peptide Mean Area Under the Curve (mAUC)</measure>
    <time_frame>Baseline (Pre-treatment) to Weeks 52 and 104</time_frame>
    <description>C-peptide is a substance released by the pancreas into the bloodstream in equal amounts to insulin and reflects how much insulin pancreatic beta cells are making. The standardized MMTT evaluates whether beta cells are producing endogenous insulin. The MMTT was performed in the morning and blood samples for C-peptide collected at baseline (pre-meal) and 15, 30, 60, 90, 120, 150, 180, 210, and 240 minutes post-meal. C-peptide mAUC was calculated using the trapezoidal rule over the 4-hour time period. Larger numbers are preferable (better) in these mAUC results: more insulin being produced reflects less severe disease. C-peptide levels in the serum (e.g., mAUC following a standardized MMTT) compared to control group at 1 year post treatment initiation for the evaluation of investigational products intended to preserve endogenous beta-cell function in T1DM trials is recognized by the Center for Drug Evaluation and Research (CDER) at the FDA as a valid efficacy endpoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Average Insulin Use in Units Per Kilogram Body Weight Per Day</measure>
    <time_frame>Baseline (Pre-treatment) to Weeks 24, 52, and 104</time_frame>
    <description>The need to use exogenous insulin is an indication that the body is not producing enough endogenous insulin. Higher amounts of insulin use indicate higher disease activity. Insulin use was collected each day for 5 days prior to the visit. Average insulin use per kg is the average insulin use over the 5 days prior to the visit divided by the participant's weight in kg.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Average Insulin Use Per Kg, Mixed Model</measure>
    <time_frame>Baseline (Pre-treatment) to Weeks 12, 24, 39, 52, 78, and 104</time_frame>
    <description>The need to use exogenous insulin is an indication that the body is not producing enough endogenous insulin. Higher amounts of insulin use indicate higher disease activity. Insulin use was collected each day for 5 days prior to the visit. Average insulin use per kg is the average insulin use over the 5 days prior to the visit divided by the participant's weight in kg.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Hemoglobin A1c</measure>
    <time_frame>Baseline (Pre-treatment) to Weeks 24, 52, and 104</time_frame>
    <description>Glycosylated hemoglobin (HbA1c) is a measure of the average plasma concentration of blood sugar (glucose) over the previous three months and measures the level of optimal management of underlying disease. An HbA1c of 5.6% or less is considered normal. HbA1c of 6.5% or higher is typical for individuals with Type 1 Diabetes mellitus (T1DM). The closer HbA1c levels are to normal, the better controlled the disease is.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Hemoglobin A1C (HbA1c) Level in Participants, Mixed Model</measure>
    <time_frame>Baseline (Pre-treatment) to Weeks 12, 24, 39, 52, 78, and 104</time_frame>
    <description>Glycosylated hemoglobin (HbA1c) is a measure of the average plasma concentration of blood sugar (glucose) over the previous three months and measures the level of optimal management of underlying disease. An HbA1c of 5.6% or less is considered normal. HbA1c of 6.5% or higher is typical for individuals with Type 1 Diabetes mellitus (T1DM). The closer HbA1c levels are to normal, the better controlled the disease is.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Experienced at Least One Major Hypoglycemic Event After Treatment Initiation</measure>
    <time_frame>Day 0 (Treatment Initiation) to Weeks 52 and 104</time_frame>
    <description>Major hypoglycemic adverse events are defined as: Blood glucose concentration &lt; 40 mg/dL (Grades 3-5, NCI-CTCAE version 4.03*), or hypoglycemic events involving seizure or loss of consciousness (coma) or requiring assistance from another individual in order to recover.&#xD;
*NCI-CTCAE: National Cancer Institute Common Terminology Criteria for Adverse Events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Experienced Infusion-Related Adverse Events</measure>
    <time_frame>Day 0 (Treatment Initiation) to Week 52</time_frame>
    <description>An infusion/dose reaction is defined as an adverse event occurring during and within 24 hours after the infusion or subcutaneous injection of tocilizumab. This may include hypersensitivity reactions or anaphylactic reactions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Experienced Hypersensitivity Adverse Events</measure>
    <time_frame>Day 0 (Treatment Initiation) to Week 52</time_frame>
    <description>Signs of a possible hypersensitivity reaction to the study drug include but are not limited to:&#xD;
Fever, chills, pruritus, urticaria, angioedema, and skin rash&#xD;
Cardiopulmonary reactions, including chest pain, dyspnea, hypotension or hypertension</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">136</enrollment>
  <condition>Type 1 Diabetes Mellitus</condition>
  <condition>New-onset Type 1 Diabetes Mellitus</condition>
  <condition>T1DM</condition>
  <condition>T1D</condition>
  <arm_group>
    <arm_group_label>Tocilizumab (TCZ) + SOC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive intravenous (IV) infusions of either 8.0 mg/kg (body weight â‰¥30 kg) or 10.0 mg/kg (body weight &lt;30kg) tocilizumab every 4 weeks for 24 weeks. Participants will also receive standard intensive diabetes management (in accordance with the American Diabetes Association guidelines [Standard of Care, SOC])</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tocilizumab Placebo Group + SOC</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will receive IV infusions of either 8.0 mg/kg (body weight â‰¥ 30kg) or 10.0 mg/kg (body weight &lt;30kg) placebo every 4 weeks for 24 weeks. Participants will also receive standard intensive diabetes management (in accordance with the American Diabetes Association guidelines [Standard of Care, SOC])</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tocilizumab (TCZ)</intervention_name>
    <description>Subjects assigned to this group will receive tocilizumab intravenous (IV) infusions of either 8.0 mg/kg (body weight â‰¥ 30kg) or 10.0 mg/kg (body weight &lt;30kg) every 4 weeks for 24 weeks.</description>
    <arm_group_label>Tocilizumab (TCZ) + SOC</arm_group_label>
    <other_name>ActemraÂ®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subjects assigned to this group will receive placebo intravenous (IV) infusions of either 8.0 mg/kg (body weight â‰¥ 30kg) or 10.0 mg/kg (body weight &lt;30kg) every 4 weeks for 24 weeks.</description>
    <arm_group_label>Tocilizumab Placebo Group + SOC</arm_group_label>
    <other_name>Placebo for Tocilizumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard of Care</intervention_name>
    <description>Participants will also receive standard intensive diabetes management (in accordance with the American Diabetes Association guidelines [Standard of Care, SOC])</description>
    <arm_group_label>Tocilizumab (TCZ) + SOC</arm_group_label>
    <arm_group_label>Tocilizumab Placebo Group + SOC</arm_group_label>
    <other_name>SOC</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female aged 6-45 years*&#xD;
&#xD;
             -*Current Institutional Review Board (IRB)-approved age eligibility criteria is&#xD;
             restricted to subjects 6 to 17 years of age at time of study enrollment&#xD;
&#xD;
          2. Diagnosis of type 1 diabetes mellitus (T1DM), using the American Diabetes Association&#xD;
             T1DM criteria, within 100 days of study enrollment&#xD;
&#xD;
          3. Positive for at least one diabetes-related autoantibody, including but not limited to:&#xD;
&#xD;
               1. Glutamate decarboxylase (GAD-65)&#xD;
&#xD;
               2. Insulin, if obtained within 10 days of the onset of exogenous insulin therapy&#xD;
&#xD;
               3. Insulinoma antigen-2 (IA-2)&#xD;
&#xD;
               4. Zinc transporter-8 (ZnT8)&#xD;
&#xD;
          4. Peak stimulated C-peptide level â‰¥ 0.2 pmol/mL following a mixed-meal tolerance test&#xD;
             (MMTT) conducted at least 21 days from diagnosis and within 37 days of randomization&#xD;
             (V0)&#xD;
&#xD;
          5. Signed informed consent (and informed assent of minor, if applicable).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Severe reaction or anaphylaxis to human, humanized or murine monoclonal antibodies&#xD;
&#xD;
          2. History of malignancy or serious uncontrolled cardiovascular, nervous system,&#xD;
             pulmonary, renal, or gastrointestinal disease, or significant dyslipidemia&#xD;
&#xD;
          3. Any history of recent serious bacterial, viral, fungal, or other opportunistic&#xD;
             infections&#xD;
&#xD;
          4. Have serologic evidence of current or past HIV (Human immunodeficiency virus),&#xD;
             Hepatitis B, or Hepatitis C&#xD;
&#xD;
          5. Positive QuantiFERON Tuberculosis (TB) test, history of TB, or active TB infection&#xD;
&#xD;
          6. Active infection with Epstein-Barr virus (EBV) as defined by EBV viral load â‰¥10,000&#xD;
             copies per mL of whole blood&#xD;
&#xD;
          7. Active infection with Cytomegalovirus (CMV) as defined by CMV viral load â‰¥10,000&#xD;
             copies per mL of whole blood&#xD;
&#xD;
          8. Diagnosis of liver disease or elevated hepatic enzymes, as defined by Alanine&#xD;
             aminotransferase (ALT), Aspartate aminotransferase (AST), or both &gt; 1.5 x the upper&#xD;
             limit of age-determined normal (ULN) or total bilirubin &gt; ULN&#xD;
&#xD;
          9. Current or prior treatment that is known to cause a significant, ongoing change in the&#xD;
             course of T1D or immunologic status&#xD;
&#xD;
         10. Current or prior (within last 30 days) use of drugs other than insulin to treat&#xD;
             hyperglycemia (e.g. metformin, sulfonylureas, glinides, thiazolidinediones, exenatide,&#xD;
             liraglutide, Dipeptidyl peptidase-4 Intravenous (DPP-IV) inhibitors, or amylin)&#xD;
&#xD;
         11. Current use of any medication known to significantly influence glucose tolerance&#xD;
             (e.g., atypical antipsychotics, diphenylhydantoin, niacin)&#xD;
&#xD;
         12. Any of the following hematologic abnormalities, confirmed by repeat tests:&#xD;
&#xD;
               1. White blood count &lt;3,000/microL or &gt;14,000/microL&#xD;
&#xD;
               2. Lymphocyte count &lt;500/microL&#xD;
&#xD;
               3. Platelet count &lt;150,000 /microL&#xD;
&#xD;
               4. Hemoglobin &lt;8.5 g/dL&#xD;
&#xD;
               5. . Neutrophil count &lt;2,000 cells/microL.&#xD;
&#xD;
         13. Females who are pregnant, lactating, or planning on pregnancy during the 2- year study&#xD;
             period&#xD;
&#xD;
         14. History or diagnoses of other autoimmune diseases with the exception of stable thyroid&#xD;
             or celiac disease&#xD;
&#xD;
         15. History of alcohol, drug or chemical abuse within 1 year prior to study eligibility&#xD;
             screening evaluation&#xD;
&#xD;
         16. Any medical or psychological condition that in the opinion of the principal&#xD;
             investigator would interfere with safe completion of the trial&#xD;
&#xD;
         17. Prior participation in a clinical trial that could increase risks associated with this&#xD;
             clinical trial&#xD;
&#xD;
         18. Receipt of live vaccine (e.g. varicella, measles, mumps, rubella, cold-attenuated&#xD;
             intranasal influenza vaccine, bacillus Calmette-GuÃ©rin, and small pox) in the 6 weeks&#xD;
             before randomization&#xD;
&#xD;
         19. High lipid levels (fasting Low-density lipoprotein (LDL) cholesterol â‰¥160 mg/dL)&#xD;
&#xD;
         20. History of significant allergy (e.g. anaphylaxis) to milk or soy proteins.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carla Greenbaum</last_name>
    <role>Study Chair</role>
    <affiliation>Benaroya Research Institute at Virginia Mason: Diabetes Research Program</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jane Buckner, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Benaroya Research Institute at Virginia Mason: Diabetes Research Program</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale University School of Medicine: Diabetes Endocrinology Research Center</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06519</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami: Diabetes Research Institute</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of South Florida: Diabetes Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University Health - Riley Hospital for Children</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harvard University, Joslin Diabetes Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>002215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Mercy Hospital</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University, Naomi Berrie Diabetes Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanford Research</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Benaroya Research Institute</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Children's Hospital at Westmead: Kids Research Institute</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>Westmead 2145</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lady Cilento Children's Hospital: Department of Endocrinology</name>
      <address>
        <city>South Brisbane</city>
        <state>Queensland</state>
        <zip>4101</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Canada</country>
  </removed_countries>
  <link>
    <url>https://www.niaid.nih.gov/</url>
    <description>National Institute of Allergy and Infectious Diseases (NIAID) website</description>
  </link>
  <link>
    <url>https://www.niaid.nih.gov/about/dait</url>
    <description>Division of Allergy, Immunology, and Transplantation (DAIT) website</description>
  </link>
  <link>
    <url>http://www.immunetolerance.org/</url>
    <description>Immune Tolerance Network (ITN) website</description>
  </link>
  <link>
    <url>http://www.extendstudy.org/about-extend</url>
    <description>EXTEND's study-specific ITN website</description>
  </link>
  <link>
    <url>http://www.diabetes.org/diabetes-basics/type-1/?loc=util-header_type1</url>
    <description>American Diabetes Association information on Type 1 Diabetes</description>
  </link>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>November 13, 2014</study_first_submitted>
  <study_first_submitted_qc>November 17, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 18, 2014</study_first_posted>
  <results_first_submitted>July 22, 2021</results_first_submitted>
  <results_first_submitted_qc>July 22, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">August 17, 2021</results_first_posted>
  <disposition_first_submitted>January 22, 2020</disposition_first_submitted>
  <disposition_first_submitted_qc>January 22, 2020</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">February 5, 2020</disposition_first_posted>
  <last_update_submitted>August 16, 2021</last_update_submitted>
  <last_update_submitted_qc>August 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>interleukin-6 (IL-6) receptor inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The plan is to share data upon completion of the study in: Immunology Database and Analysis Portal (ImmPort), a long-term archive of clinical and mechanistic data from DAIT-funded grants and contracts.</ipd_description>
    <ipd_time_frame>On average, within 24 months after database lock for the trial.</ipd_time_frame>
    <ipd_access_criteria>Open access.</ipd_access_criteria>
    <ipd_url>https://www.immport.org/home</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 13, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/37/NCT02293837/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 2, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/37/NCT02293837/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were screened from February 11, 2015 to Jun 21, 2018 at 17 sites in the US and two sites in Australia. March 12, 2015 was the actual date on which the first participant was enrolled in this clinical study.</recruitment_details>
      <pre_assignment_details>Before initiating the study in the pediatric group (6-17 years old), adults (18-45 years old) were randomized 2:1 to tocilizumab or placebo, respectively. After at least 30 adults completed 12 weeks of treatment, the Data and Safety Monitoring Board (DSMB) and FDA reviewed the available data and allowed the enrollment of children 6-17 years old.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Tocilizumab (TCZ) in Pediatric Participants</title>
          <description>Participants received intravenous (IV) infusions of either 8.0 mg/kg (body weight &gt;=30 kg) or 10.0 mg/kg (body weight &lt;30kg) tocilizumab every 4 weeks for 24 weeks. The dose was capped at 800 mg. Pediatric participants were 6 to 17 years old inclusive.</description>
        </group>
        <group group_id="P2">
          <title>Placebo in Pediatric Participants</title>
          <description>Participants received IV placebo infusions of saline of equal volume and appearance to the treatment. Pediatric participants were 6 to 17 years old inclusive.</description>
        </group>
        <group group_id="P3">
          <title>Tocilizumab (TCZ) in Adult Participants</title>
          <description>Participants received intravenous (IV) infusions of either 8.0 mg/kg (body weight &gt;=30 kg) or 10.0 mg/kg (body weight &lt;30kg) tocilizumab every 4 weeks for 24 weeks. The dose was capped at 800 mg. Adult participants were 18 to 45 years old inclusive.</description>
        </group>
        <group group_id="P4">
          <title>Placebo in Adult Participants</title>
          <description>Participants received IV placebo infusions of saline of equal volume and appearance to the treatment. Adult participants were 18 to 45 years old inclusive.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="54"/>
                <participants group_id="P2" count="27"/>
                <participants group_id="P3" count="35">1 randomized adult was never treated</participants>
                <participants group_id="P4" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="51"/>
                <participants group_id="P2" count="23"/>
                <participants group_id="P3" count="31"/>
                <participants group_id="P4" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>COVID-19 Related</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant ill and could not be infused</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Randomized participants in each cohort were randomized 2:1 to tocilizumab or placebo, respectively.</population>
      <group_list>
        <group group_id="B1">
          <title>Tocilizumab (TCZ) in Pediatric Participants</title>
          <description>Participants received intravenous (IV) infusions of either 8.0 mg/kg (body weight &gt;=30 kg) or 10.0 mg/kg (body weight &lt;30kg) tocilizumab every 4 weeks for 24 weeks. The dose was capped at 800 mg. Pediatric participants were 6 to 17 years old inclusive.</description>
        </group>
        <group group_id="B2">
          <title>Placebo in Pediatric Participants</title>
          <description>Participants received IV placebo infusions of saline of equal volume and appearance to the treatment. Pediatric participants were 6 to 17 years old inclusive.</description>
        </group>
        <group group_id="B3">
          <title>Tocilizumab (TCZ) in Adult Participants</title>
          <description>Participants received intravenous (IV) infusions of either 8.0 mg/kg (body weight &gt;=30 kg) or 10.0 mg/kg (body weight &lt;30kg) tocilizumab every 4 weeks for 24 weeks. The dose was capped at 800 mg. Adult participants were 18 to 45 years old inclusive.</description>
        </group>
        <group group_id="B4">
          <title>Placebo in Adult Participants</title>
          <description>Participants received IV placebo infusions of saline of equal volume and appearance to the treatment. Adult participants were 18 to 45 years old inclusive.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="54"/>
            <count group_id="B2" value="27"/>
            <count group_id="B3" value="35"/>
            <count group_id="B4" value="20"/>
            <count group_id="B5" value="136"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11.1" spread="2.9"/>
                    <measurement group_id="B2" value="11.1" spread="2.5"/>
                    <measurement group_id="B3" value="27.9" spread="7.4"/>
                    <measurement group_id="B4" value="29.2" spread="9.3"/>
                    <measurement group_id="B5" value="18.1" spread="10.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="57"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="32"/>
                    <measurement group_id="B4" value="19"/>
                    <measurement group_id="B5" value="125"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="32"/>
                    <measurement group_id="B4" value="19"/>
                    <measurement group_id="B5" value="118"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="35"/>
                    <measurement group_id="B4" value="20"/>
                    <measurement group_id="B5" value="131"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <description>BMI is a person's weight in kilograms divided by the square of height in meters. For more information regarding BMI, visit the Centers for Disease Control and Prevention (CDC) website, &quot;How Do I Interpret Body Mass Index Information&quot; at:&#xD;
https://www.cdc.gov/healthyweight/assessing/bmi/index.html</description>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19.8" spread="3.8"/>
                    <measurement group_id="B2" value="19.1" spread="3.3"/>
                    <measurement group_id="B3" value="24.2" spread="3.9"/>
                    <measurement group_id="B4" value="25.4" spread="3.5"/>
                    <measurement group_id="B5" value="21.6" spread="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>2-hour C-peptide Mean Area Under the Curve (mAUC) Result in Response to Standardized Mixed Meal Tol</title>
          <description>C-peptide is released by the pancreas into the bloodstream in equal amounts to insulin and reflects how much insulin pancreatic beta cells are making. The MMTT was performed in the morning and blood samples for C-peptide collected at baseline (pre-meal) and various minutes post-meal. C-peptide AUC was calculated using the trapezoidal rule over the 2-hour time period. Results of the stimulated 2-hour (e.g., 120 minutes) post-meal C-peptide AUC are provided. Larger numbers are preferable (better) in these AUC results: more insulin being produced reflects less severe disease.</description>
          <units>pmol/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.73" spread="0.44"/>
                    <measurement group_id="B2" value="0.66" spread="0.32"/>
                    <measurement group_id="B3" value="0.77" spread="0.24"/>
                    <measurement group_id="B4" value="0.97" spread="0.69"/>
                    <measurement group_id="B5" value="0.76" spread="0.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hemoglobin A1C (HbA1c) Level</title>
          <description>Glycosylated hemoglobin (HbA1c) is a measure of the average plasma concentration of blood sugar (glucose) over the previous three months and measures the level of optimal management of underlying disease. An HbA1c of 5.6% or less is considered normal. HbA1c of 6.5% or higher is typical for individuals with Type 1 Diabetes mellitus (T1DM). The closer HbA1c levels are to normal, the better controlled the disease is.</description>
          <units>percent (%)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.79" spread="1.03"/>
                    <measurement group_id="B2" value="6.86" spread="0.55"/>
                    <measurement group_id="B3" value="6.48" spread="1.08"/>
                    <measurement group_id="B4" value="6.28" spread="0.73"/>
                    <measurement group_id="B5" value="6.65" spread="0.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Average Insulin Use Per Kilogram Body Weight</title>
          <description>The need to use exogenous insulin is an indication that the body is not producing enough endogenous insulin. Higher amounts of insulin use indicate higher disease activity.</description>
          <units>Units per Kilogram Body Weight per Day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.39" spread="0.24"/>
                    <measurement group_id="B2" value="0.38" spread="0.19"/>
                    <measurement group_id="B3" value="0.28" spread="0.15"/>
                    <measurement group_id="B4" value="0.30" spread="0.21"/>
                    <measurement group_id="B5" value="0.35" spread="0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Days from Type 1 Diabetes Mellitus (T1DM) Diagnosis to Randomization</title>
          <description>Inclusion criteria included being diagnosed with type 1 diabetes within 100 days of enrollment. Diagnosis was based on the American Diabetes Association T1DM criteria.</description>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="85.9" spread="15.5"/>
                    <measurement group_id="B2" value="83.9" spread="16.7"/>
                    <measurement group_id="B3" value="82.5" spread="13.6"/>
                    <measurement group_id="B4" value="84.6" spread="12.4"/>
                    <measurement group_id="B5" value="84.4" spread="14.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in 2-Hour C-peptide Mean Area Under the Curve (mAUC) in Pediatric Participants</title>
        <description>C-peptide is a substance released by the pancreas into the bloodstream in equal amounts to insulin and reflects how much insulin pancreatic beta cells are making. The standardized MMTT evaluates whether beta cells are producing endogenous insulin. The MMTT was performed in the morning and blood samples for C-peptide collected at baseline (pre-meal) and 15, 30, 60, 90, 120, 150, 180, 210, and 240 minutes post-meal. C-peptide mAUC was calculated using the trapezoidal rule over the 2-hour time period. Larger numbers are preferable (better) in these mAUC results: more insulin being produced reflects less severe disease. C-peptide levels in the serum (e.g., mAUC following a standardized MMTT) compared to control group at 1 year post treatment initiation for the evaluation of investigational products intended to preserve endogenous beta-cell function in T1DM trials is recognized by the Center for Drug Evaluation and Research (CDER) at the FDA as a valid efficacy endpoint.</description>
        <time_frame>Baseline (Pre-treatment) to Week 52</time_frame>
        <population>The modified intent to treat population includes all randomized participants who received any dose of assigned study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Tocilizumab (TCZ) in Pediatric Participants</title>
            <description>Participants received intravenous (IV) infusions of either 8.0 mg/kg (body weight &gt;=30 kg) or 10.0 mg/kg (body weight &lt;30kg) tocilizumab every 4 weeks for 24 weeks. The dose was capped at 800 mg. Pediatric participants were 6 to 17 years old inclusive.</description>
          </group>
          <group group_id="O2">
            <title>Placebo in Pediatric Participants</title>
            <description>Participants received IV placebo infusions of saline of equal volume and appearance to the treatment. Pediatric participants were 6 to 17 years old inclusive.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 2-Hour C-peptide Mean Area Under the Curve (mAUC) in Pediatric Participants</title>
          <description>C-peptide is a substance released by the pancreas into the bloodstream in equal amounts to insulin and reflects how much insulin pancreatic beta cells are making. The standardized MMTT evaluates whether beta cells are producing endogenous insulin. The MMTT was performed in the morning and blood samples for C-peptide collected at baseline (pre-meal) and 15, 30, 60, 90, 120, 150, 180, 210, and 240 minutes post-meal. C-peptide mAUC was calculated using the trapezoidal rule over the 2-hour time period. Larger numbers are preferable (better) in these mAUC results: more insulin being produced reflects less severe disease. C-peptide levels in the serum (e.g., mAUC following a standardized MMTT) compared to control group at 1 year post treatment initiation for the evaluation of investigational products intended to preserve endogenous beta-cell function in T1DM trials is recognized by the Center for Drug Evaluation and Research (CDER) at the FDA as a valid efficacy endpoint.</description>
          <population>The modified intent to treat population includes all randomized participants who received any dose of assigned study treatment.</population>
          <units>pmol/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.337" lower_limit="-0.39" upper_limit="-0.28"/>
                    <measurement group_id="O2" value="-0.391" lower_limit="-0.47" upper_limit="-0.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 52; Primary imputation method used for missing Week 52 mAUC.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.277</p_value>
            <p_value_desc>P-value comes from an analysis of covariance with outcome variable of change in mAUC from screening and covariates of treatment, screening mAUC, and age.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in 2-Hour C-peptide Mean Area Under the Curve (mAUC)</title>
        <description>C-peptide is a substance released by the pancreas into the bloodstream in equal amounts to insulin and reflects how much insulin pancreatic beta cells are making. The standardized MMTT evaluates whether beta cells are producing endogenous insulin. The MMTT was performed in the morning and blood samples for C-peptide collected at baseline (pre-meal) and 15, 30, 60, 90, 120, 150, 180, 210, and 240 minutes post-meal. C-peptide mAUC was calculated using the trapezoidal rule over the 2-hour time period. Larger numbers are preferable (better) in these mAUC results: more insulin being produced reflects less severe disease. C-peptide levels in the serum (e.g., mAUC following a standardized MMTT) compared to control group at 1 year post treatment initiation for the evaluation of investigational products intended to preserve endogenous beta-cell function in T1DM trials is recognized by the Center for Drug Evaluation and Research (CDER) at the FDA as a valid efficacy endpoint.</description>
        <time_frame>Baseline (Pre-treatment) to Weeks 24, 52, and 104</time_frame>
        <population>Modified intent to treat population includes all randomized participants who received any dose of assigned study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Tocilizumab (TCZ) in Pediatric Participants</title>
            <description>Participants received intravenous (IV) infusions of either 8.0 mg/kg (body weight &gt;=30 kg) or 10.0 mg/kg (body weight &lt;30kg) tocilizumab every 4 weeks for 24 weeks. The dose was capped at 800 mg. Pediatric participants were 6 to 17 years old inclusive.</description>
          </group>
          <group group_id="O2">
            <title>Placebo in Pediatric Participants</title>
            <description>Participants received IV placebo infusions of saline of equal volume and appearance to the treatment. Pediatric participants were 6 to 17 years old inclusive.</description>
          </group>
          <group group_id="O3">
            <title>Tocilizumab (TCZ) in Adult Participants</title>
            <description>Participants received intravenous (IV) infusions of either 8.0 mg/kg (body weight &gt;=30 kg) or 10.0 mg/kg (body weight &lt;30kg) tocilizumab every 4 weeks for 24 weeks. The dose was capped at 800 mg. Adult participants were 18 to 45 years old inclusive.</description>
          </group>
          <group group_id="O4">
            <title>Placebo in Adult Participants</title>
            <description>Participants received IV placebo infusions of saline of equal volume and appearance to the treatment. Adult participants were 18 to 45 years old inclusive.</description>
          </group>
          <group group_id="O5">
            <title>Tocilizumab (TCZ) in Pooled Participants</title>
            <description>Participants received intravenous (IV) infusions of either 8.0 mg/kg (body weight &gt;=30 kg) or 10.0 mg/kg (body weight &lt;30kg) tocilizumab every 4 weeks for 24 weeks. The dose was capped at 800 mg. Pooled participants are the pediatric and adult participants who received TCZ combined.</description>
          </group>
          <group group_id="O6">
            <title>Placebo in Pooled Participants</title>
            <description>Participants received IV placebo infusions of saline of equal volume and appearance to the treatment. Pooled participants are the pediatric and adult participants who received placebo combined.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 2-Hour C-peptide Mean Area Under the Curve (mAUC)</title>
          <description>C-peptide is a substance released by the pancreas into the bloodstream in equal amounts to insulin and reflects how much insulin pancreatic beta cells are making. The standardized MMTT evaluates whether beta cells are producing endogenous insulin. The MMTT was performed in the morning and blood samples for C-peptide collected at baseline (pre-meal) and 15, 30, 60, 90, 120, 150, 180, 210, and 240 minutes post-meal. C-peptide mAUC was calculated using the trapezoidal rule over the 2-hour time period. Larger numbers are preferable (better) in these mAUC results: more insulin being produced reflects less severe disease. C-peptide levels in the serum (e.g., mAUC following a standardized MMTT) compared to control group at 1 year post treatment initiation for the evaluation of investigational products intended to preserve endogenous beta-cell function in T1DM trials is recognized by the Center for Drug Evaluation and Research (CDER) at the FDA as a valid efficacy endpoint.</description>
          <population>Modified intent to treat population includes all randomized participants who received any dose of assigned study treatment.</population>
          <units>pmol/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="34"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="88"/>
                <count group_id="O6" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="54"/>
                    <count group_id="O2" value="26"/>
                    <count group_id="O3" value="33"/>
                    <count group_id="O4" value="20"/>
                    <count group_id="O5" value="87"/>
                    <count group_id="O6" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.200" lower_limit="-0.26" upper_limit="-0.14"/>
                    <measurement group_id="O2" value="-0.164" lower_limit="-0.25" upper_limit="-0.08"/>
                    <measurement group_id="O3" value="-0.072" lower_limit="-0.17" upper_limit="0.03"/>
                    <measurement group_id="O4" value="-0.097" lower_limit="-0.23" upper_limit="0.03"/>
                    <measurement group_id="O5" value="-0.152" lower_limit="-0.20" upper_limit="-0.10"/>
                    <measurement group_id="O6" value="-0.134" lower_limit="-0.21" upper_limit="-0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="25"/>
                    <count group_id="O3" value="33"/>
                    <count group_id="O4" value="20"/>
                    <count group_id="O5" value="86"/>
                    <count group_id="O6" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.339" lower_limit="-0.40" upper_limit="-0.28"/>
                    <measurement group_id="O2" value="-0.397" lower_limit="-0.48" upper_limit="-0.31"/>
                    <measurement group_id="O3" value="-0.186" lower_limit="-0.29" upper_limit="-0.08"/>
                    <measurement group_id="O4" value="-0.267" lower_limit="-0.40" upper_limit="-0.13"/>
                    <measurement group_id="O5" value="-0.287" lower_limit="-0.34" upper_limit="-0.23"/>
                    <measurement group_id="O6" value="-0.328" lower_limit="-0.41" upper_limit="-0.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="49"/>
                    <count group_id="O2" value="22"/>
                    <count group_id="O3" value="29"/>
                    <count group_id="O4" value="19"/>
                    <count group_id="O5" value="78"/>
                    <count group_id="O6" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.495" lower_limit="-0.55" upper_limit="-0.44"/>
                    <measurement group_id="O2" value="-0.556" lower_limit="-0.64" upper_limit="-0.47"/>
                    <measurement group_id="O3" value="-0.384" lower_limit="-0.49" upper_limit="-0.28"/>
                    <measurement group_id="O4" value="-0.388" lower_limit="-0.52" upper_limit="-0.25"/>
                    <measurement group_id="O5" value="-0.461" lower_limit="-0.52" upper_limit="-0.40"/>
                    <measurement group_id="O6" value="-0.463" lower_limit="-0.54" upper_limit="-0.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 24</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.499</p_value>
            <p_value_desc>P-value comes from an analysis of covariance with outcome variable of change in mAUC from screening and covariates of treatment, screening mAUC, and age.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 52</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.267</p_value>
            <p_value_desc>P-value comes from an analysis of covariance with outcome variable of change in mAUC from screening and covariates of treatment, screening mAUC, and age.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 104</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.226</p_value>
            <p_value_desc>P-value comes from an analysis of covariance with outcome variable of change in mAUC from screening and covariates of treatment, screening mAUC, and age.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 24</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.758</p_value>
            <p_value_desc>P-value comes from an analysis of covariance with outcome variable of change in mAUC from screening and covariates of treatment, screening mAUC, and age.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 52</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.341</p_value>
            <p_value_desc>P-value comes from an analysis of covariance with outcome variable of change in mAUC from screening and covariates of treatment, screening mAUC, and age.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 104</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.969</p_value>
            <p_value_desc>P-value comes from an analysis of covariance with outcome variable of change in mAUC from screening and covariates of treatment, screening mAUC, and age.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Week 24</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.689</p_value>
            <p_value_desc>P-value comes from an analysis of covariance with outcome variable of change in mAUC from screening and covariates of treatment, screening mAUC, and age.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Week 52</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.400</p_value>
            <p_value_desc>P-value comes from an analysis of covariance with outcome variable of change in mAUC from screening and covariates of treatment, screening mAUC, and age.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Week 104</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.969</p_value>
            <p_value_desc>P-value comes from an analysis of covariance with outcome variable of change in mAUC from screening and covariates of treatment, screening mAUC, and age.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>2-Hour C-peptide Mean Area Under the Curve (mAUC), Mixed Model</title>
        <description>C-peptide is a substance released by the pancreas into the bloodstream in equal amounts to insulin and reflects how much insulin pancreatic beta cells are making. The standardized MMTT evaluates whether beta cells are producing endogenous insulin. The MMTT was performed in the morning and blood samples for C-peptide collected at baseline (pre-meal) and 15, 30, 60, 90, 120, 150, 180, 210, and 240 minutes post-meal. C-peptide mAUC was calculated using the trapezoidal rule over the 2-hour time period. Larger numbers are preferable (better) in these mAUC results: more insulin being produced reflects less severe disease. C-peptide levels in the serum (e.g., mAUC following a standardized MMTT) compared to control group at 1 year post treatment initiation for the evaluation of investigational products intended to preserve endogenous beta-cell function in T1DM trials is recognized by the Center for Drug Evaluation and Research (CDER) at the FDA as a valid efficacy endpoint.</description>
        <time_frame>Baseline (Pre-treatment), Weeks 12, 24, 39, 52, 78, and 104</time_frame>
        <population>The modified intent to treat population includes all randomized participants who received any dose of assigned study treatment. The model only included subjects with at least 1 post-screening assessment. One mITT subject did not have a post-screening MMTT and this subject is not included.</population>
        <group_list>
          <group group_id="O1">
            <title>Tocilizumab (TCZ) in Pediatric Participants</title>
            <description>Participants received intravenous (IV) infusions of either 8.0 mg/kg (body weight &gt;=30 kg) or 10.0 mg/kg (body weight &lt;30kg) tocilizumab every 4 weeks for 24 weeks. The dose was capped at 800 mg. Pediatric participants were 6 to 17 years old inclusive.</description>
          </group>
          <group group_id="O2">
            <title>Placebo in Pediatric Participants</title>
            <description>Participants received IV placebo infusions of saline of equal volume and appearance to the treatment. Pediatric participants were 6 to 17 years old inclusive.</description>
          </group>
          <group group_id="O3">
            <title>Tocilizumab (TCZ) in Adult Participants</title>
            <description>Participants received intravenous (IV) infusions of either 8.0 mg/kg (body weight &gt;=30 kg) or 10.0 mg/kg (body weight &lt;30kg) tocilizumab every 4 weeks for 24 weeks. The dose was capped at 800 mg. Adult participants were 18 to 45 years old inclusive.</description>
          </group>
          <group group_id="O4">
            <title>Placebo in Adult Participants</title>
            <description>Participants received IV placebo infusions of saline of equal volume and appearance to the treatment. Adult participants were 18 to 45 years old inclusive.</description>
          </group>
          <group group_id="O5">
            <title>Tocilizumab (TCZ) in Pooled Participants</title>
            <description>Participants received intravenous (IV) infusions of either 8.0 mg/kg (body weight &gt;=30 kg) or 10.0 mg/kg (body weight &lt;30kg) tocilizumab every 4 weeks for 24 weeks. The dose was capped at 800 mg. Pooled participants are the pediatric and adult participants who received TCZ combined.</description>
          </group>
          <group group_id="O6">
            <title>Placebo in Pooled Participants</title>
            <description>Participants received IV placebo infusions of saline of equal volume and appearance to the treatment. Pooled participants are the pediatric and adult participants who received placebo combined.</description>
          </group>
        </group_list>
        <measure>
          <title>2-Hour C-peptide Mean Area Under the Curve (mAUC), Mixed Model</title>
          <description>C-peptide is a substance released by the pancreas into the bloodstream in equal amounts to insulin and reflects how much insulin pancreatic beta cells are making. The standardized MMTT evaluates whether beta cells are producing endogenous insulin. The MMTT was performed in the morning and blood samples for C-peptide collected at baseline (pre-meal) and 15, 30, 60, 90, 120, 150, 180, 210, and 240 minutes post-meal. C-peptide mAUC was calculated using the trapezoidal rule over the 2-hour time period. Larger numbers are preferable (better) in these mAUC results: more insulin being produced reflects less severe disease. C-peptide levels in the serum (e.g., mAUC following a standardized MMTT) compared to control group at 1 year post treatment initiation for the evaluation of investigational products intended to preserve endogenous beta-cell function in T1DM trials is recognized by the Center for Drug Evaluation and Research (CDER) at the FDA as a valid efficacy endpoint.</description>
          <population>The modified intent to treat population includes all randomized participants who received any dose of assigned study treatment. The model only included subjects with at least 1 post-screening assessment. One mITT subject did not have a post-screening MMTT and this subject is not included.</population>
          <units>pmol/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="34"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="88"/>
                <count group_id="O6" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.60" lower_limit="0.51" upper_limit="0.69"/>
                    <measurement group_id="O2" value="0.55" lower_limit="0.42" upper_limit="0.68"/>
                    <measurement group_id="O3" value="0.72" lower_limit="0.56" upper_limit="0.89"/>
                    <measurement group_id="O4" value="0.88" lower_limit="0.67" upper_limit="1.09"/>
                    <measurement group_id="O5" value="0.65" lower_limit="0.57" upper_limit="0.74"/>
                    <measurement group_id="O6" value="0.69" lower_limit="0.57" upper_limit="0.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.55" lower_limit="0.46" upper_limit="0.63"/>
                    <measurement group_id="O2" value="0.49" lower_limit="0.37" upper_limit="0.61"/>
                    <measurement group_id="O3" value="0.68" lower_limit="0.52" upper_limit="0.84"/>
                    <measurement group_id="O4" value="0.83" lower_limit="0.62" upper_limit="1.04"/>
                    <measurement group_id="O5" value="0.60" lower_limit="0.52" upper_limit="0.69"/>
                    <measurement group_id="O6" value="0.63" lower_limit="0.52" upper_limit="0.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.48" lower_limit="0.40" upper_limit="0.56"/>
                    <measurement group_id="O2" value="0.42" lower_limit="0.30" upper_limit="0.53"/>
                    <measurement group_id="O3" value="0.63" lower_limit="0.47" upper_limit="0.79"/>
                    <measurement group_id="O4" value="0.77" lower_limit="0.56" upper_limit="0.98"/>
                    <measurement group_id="O5" value="0.54" lower_limit="0.46" upper_limit="0.62"/>
                    <measurement group_id="O6" value="0.56" lower_limit="0.45" upper_limit="0.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.42" lower_limit="0.34" upper_limit="0.50"/>
                    <measurement group_id="O2" value="0.35" lower_limit="0.24" upper_limit="0.46"/>
                    <measurement group_id="O3" value="0.59" lower_limit="0.43" upper_limit="0.75"/>
                    <measurement group_id="O4" value="0.72" lower_limit="0.51" upper_limit="0.93"/>
                    <measurement group_id="O5" value="0.49" lower_limit="0.41" upper_limit="0.57"/>
                    <measurement group_id="O6" value="0.50" lower_limit="0.39" upper_limit="0.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 78</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.30" lower_limit="0.23" upper_limit="0.37"/>
                    <measurement group_id="O2" value="0.23" lower_limit="0.12" upper_limit="0.33"/>
                    <measurement group_id="O3" value="0.50" lower_limit="0.33" upper_limit="0.66"/>
                    <measurement group_id="O4" value="0.61" lower_limit="0.40" upper_limit="0.82"/>
                    <measurement group_id="O5" value="0.38" lower_limit="0.30" upper_limit="0.46"/>
                    <measurement group_id="O6" value="0.38" lower_limit="0.28" upper_limit="0.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.18" lower_limit="0.11" upper_limit="0.25"/>
                    <measurement group_id="O2" value="0.10" lower_limit="0.00" upper_limit="0.21"/>
                    <measurement group_id="O3" value="0.41" lower_limit="0.24" upper_limit="0.58"/>
                    <measurement group_id="O4" value="0.50" lower_limit="0.28" upper_limit="0.72"/>
                    <measurement group_id="O5" value="0.27" lower_limit="0.19" upper_limit="0.35"/>
                    <measurement group_id="O6" value="0.27" lower_limit="0.16" upper_limit="0.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Screening to Week 104</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.679</p_value>
            <p_value_desc>P-value is for group difference in time trends from a longitudinal mixed effects model. Response variable was 2-hour C-peptide mAUC and covariates were treatment, study week, age, treatment*study week, age*study week.</p_value_desc>
            <method>Longitudinal mixed model</method>
            <method_desc>Random within-subject effects for intercept and study week were included assuming an unstructured covariance matrix.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Screening to Week 104</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.373</p_value>
            <p_value_desc>P-value is for group difference in time trends from a longitudinal mixed effects model. Response variable was 2-hour C-peptide mAUC and covariates were treatment, study week, age, treatment*study week, age*study week.</p_value_desc>
            <method>Longitudinal mixed model</method>
            <method_desc>Random within-subject effects for intercept and study week were included assuming an unstructured covariance matrix.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Screening to Week 104</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.395</p_value>
            <p_value_desc>P-value is for group difference in time trends from a longitudinal mixed effects model. Response variable was 2-hour C-peptide mAUC and covariates were treatment, study week, age, treatment*study week, age*study week.</p_value_desc>
            <method>Longitudinal mixed model</method>
            <method_desc>Random within-subject effects for intercept and study week were included assuming an unstructured covariance matrix.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in 4-Hour C-peptide Mean Area Under the Curve (mAUC)</title>
        <description>C-peptide is a substance released by the pancreas into the bloodstream in equal amounts to insulin and reflects how much insulin pancreatic beta cells are making. The standardized MMTT evaluates whether beta cells are producing endogenous insulin. The MMTT was performed in the morning and blood samples for C-peptide collected at baseline (pre-meal) and 15, 30, 60, 90, 120, 150, 180, 210, and 240 minutes post-meal. C-peptide mAUC was calculated using the trapezoidal rule over the 4-hour time period. Larger numbers are preferable (better) in these mAUC results: more insulin being produced reflects less severe disease. C-peptide levels in the serum (e.g., mAUC following a standardized MMTT) compared to control group at 1 year post treatment initiation for the evaluation of investigational products intended to preserve endogenous beta-cell function in T1DM trials is recognized by the Center for Drug Evaluation and Research (CDER) at the FDA as a valid efficacy endpoint.</description>
        <time_frame>Baseline (Pre-treatment) to Weeks 52 and 104</time_frame>
        <population>The modified intent to treat population includes all randomized participants who received any dose of assigned study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Tocilizumab (TCZ) in Pediatric Participants</title>
            <description>Participants received intravenous (IV) infusions of either 8.0 mg/kg (body weight &gt;=30 kg) or 10.0 mg/kg (body weight &lt;30kg) tocilizumab every 4 weeks for 24 weeks. The dose was capped at 800 mg. Pediatric participants were 6 to 17 years old inclusive.</description>
          </group>
          <group group_id="O2">
            <title>Placebo in Pediatric Participants</title>
            <description>Participants received IV placebo infusions of saline of equal volume and appearance to the treatment. Pediatric participants were 6 to 17 years old inclusive.</description>
          </group>
          <group group_id="O3">
            <title>Tocilizumab (TCZ) in Adult Participants</title>
            <description>Participants received intravenous (IV) infusions of either 8.0 mg/kg (body weight &gt;=30 kg) or 10.0 mg/kg (body weight &lt;30kg) tocilizumab every 4 weeks for 24 weeks. The dose was capped at 800 mg. Adult participants were 18 to 45 years old inclusive.</description>
          </group>
          <group group_id="O4">
            <title>Placebo in Adult Participants</title>
            <description>Participants received IV placebo infusions of saline of equal volume and appearance to the treatment. Adult participants were 18 to 45 years old inclusive.</description>
          </group>
          <group group_id="O5">
            <title>Tocilizumab (TCZ) in Pooled Participants</title>
            <description>Participants received intravenous (IV) infusions of either 8.0 mg/kg (body weight &gt;=30 kg) or 10.0 mg/kg (body weight &lt;30kg) tocilizumab every 4 weeks for 24 weeks. The dose was capped at 800 mg. Pooled participants are the pediatric and adult participants who received TCZ combined.</description>
          </group>
          <group group_id="O6">
            <title>Placebo in Pooled Participants</title>
            <description>Participants received IV placebo infusions of saline of equal volume and appearance to the treatment. Pooled participants are the pediatric and adult participants who received placebo combined.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 4-Hour C-peptide Mean Area Under the Curve (mAUC)</title>
          <description>C-peptide is a substance released by the pancreas into the bloodstream in equal amounts to insulin and reflects how much insulin pancreatic beta cells are making. The standardized MMTT evaluates whether beta cells are producing endogenous insulin. The MMTT was performed in the morning and blood samples for C-peptide collected at baseline (pre-meal) and 15, 30, 60, 90, 120, 150, 180, 210, and 240 minutes post-meal. C-peptide mAUC was calculated using the trapezoidal rule over the 4-hour time period. Larger numbers are preferable (better) in these mAUC results: more insulin being produced reflects less severe disease. C-peptide levels in the serum (e.g., mAUC following a standardized MMTT) compared to control group at 1 year post treatment initiation for the evaluation of investigational products intended to preserve endogenous beta-cell function in T1DM trials is recognized by the Center for Drug Evaluation and Research (CDER) at the FDA as a valid efficacy endpoint.</description>
          <population>The modified intent to treat population includes all randomized participants who received any dose of assigned study treatment.</population>
          <units>pmol/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="34"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="88"/>
                <count group_id="O6" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="26"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="33"/>
                    <count group_id="O4" value="20"/>
                    <count group_id="O5" value="59"/>
                    <count group_id="O6" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.325" lower_limit="-0.42" upper_limit="-0.23"/>
                    <measurement group_id="O2" value="-0.448" lower_limit="-0.60" upper_limit="-0.29"/>
                    <measurement group_id="O3" value="-0.195" lower_limit="-0.30" upper_limit="-0.09"/>
                    <measurement group_id="O4" value="-0.262" lower_limit="-0.40" upper_limit="-0.13"/>
                    <measurement group_id="O5" value="-0.252" lower_limit="-0.32" upper_limit="-0.18"/>
                    <measurement group_id="O6" value="-0.321" lower_limit="-0.42" upper_limit="-0.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="24"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="29"/>
                    <count group_id="O4" value="19"/>
                    <count group_id="O5" value="53"/>
                    <count group_id="O6" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.521" lower_limit="-0.62" upper_limit="-0.42"/>
                    <measurement group_id="O2" value="-0.635" lower_limit="-0.82" upper_limit="-0.45"/>
                    <measurement group_id="O3" value="-0.382" lower_limit="-0.49" upper_limit="-0.27"/>
                    <measurement group_id="O4" value="-0.390" lower_limit="-0.53" upper_limit="-0.25"/>
                    <measurement group_id="O5" value="-0.449" lower_limit="-0.53" upper_limit="-0.37"/>
                    <measurement group_id="O6" value="-0.448" lower_limit="-0.56" upper_limit="-0.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 52. Only participants &gt;=12 years old had the 4-hour MMTT performed.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.176</p_value>
            <p_value_desc>P-value comes from an analysis of covariance with outcome variable of change in mAUC from screening and covariates of treatment, screening mAUC, and age.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 104. Only participants &gt;=12 years old had the 4-hour MMTT performed.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.285</p_value>
            <p_value_desc>P-value comes from an analysis of covariance with outcome variable of change in mAUC from screening and covariates of treatment, screening mAUC, and age.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 52</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.435</p_value>
            <p_value_desc>P-value comes from an analysis of covariance with outcome variable of change in mAUC from screening and covariates of treatment, screening mAUC, and age.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 104</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.931</p_value>
            <p_value_desc>P-value comes from an analysis of covariance with outcome variable of change in mAUC from screening and covariates of treatment, screening mAUC, and age.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Week 52. Only participants &gt;=12 years old had the 4-hour MMTT performed.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.280</p_value>
            <p_value_desc>P-value comes from an analysis of covariance with outcome variable of change in mAUC from screening and covariates of treatment, screening mAUC, and age.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Week 104. Only participants &gt;=12 years old had the 4-hour MMTT performed.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.985</p_value>
            <p_value_desc>P-value comes from an analysis of covariance with outcome variable of change in mAUC from screening and covariates of treatment, screening mAUC, and age.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Average Insulin Use in Units Per Kilogram Body Weight Per Day</title>
        <description>The need to use exogenous insulin is an indication that the body is not producing enough endogenous insulin. Higher amounts of insulin use indicate higher disease activity. Insulin use was collected each day for 5 days prior to the visit. Average insulin use per kg is the average insulin use over the 5 days prior to the visit divided by the participant's weight in kg.</description>
        <time_frame>Baseline (Pre-treatment) to Weeks 24, 52, and 104</time_frame>
        <population>The modified intent to treat population includes all randomized participants who received any dose of assigned study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Tocilizumab (TCZ) in Pediatric Participants</title>
            <description>Participants received intravenous (IV) infusions of either 8.0 mg/kg (body weight &gt;=30 kg) or 10.0 mg/kg (body weight &lt;30kg) tocilizumab every 4 weeks for 24 weeks. The dose was capped at 800 mg. Pediatric participants were 6 to 17 years old inclusive.</description>
          </group>
          <group group_id="O2">
            <title>Placebo in Pediatric Participants</title>
            <description>Participants received IV placebo infusions of saline of equal volume and appearance to the treatment. Pediatric participants were 6 to 17 years old inclusive.</description>
          </group>
          <group group_id="O3">
            <title>Tocilizumab (TCZ) in Adult Participants</title>
            <description>Participants received intravenous (IV) infusions of either 8.0 mg/kg (body weight &gt;=30 kg) or 10.0 mg/kg (body weight &lt;30kg) tocilizumab every 4 weeks for 24 weeks. The dose was capped at 800 mg. Adult participants were 18 to 45 years old inclusive.</description>
          </group>
          <group group_id="O4">
            <title>Placebo in Adult Participants</title>
            <description>Participants received IV placebo infusions of saline of equal volume and appearance to the treatment. Adult participants were 18 to 45 years old inclusive.</description>
          </group>
          <group group_id="O5">
            <title>Tocilizumab (TCZ) in Pooled Participants</title>
            <description>Participants received intravenous (IV) infusions of either 8.0 mg/kg (body weight &gt;=30 kg) or 10.0 mg/kg (body weight &lt;30kg) tocilizumab every 4 weeks for 24 weeks. The dose was capped at 800 mg. Pooled participants are the pediatric and adult participants who received TCZ combined.</description>
          </group>
          <group group_id="O6">
            <title>Placebo in Pooled Participants</title>
            <description>Participants received IV placebo infusions of saline of equal volume and appearance to the treatment. Pooled participants are the pediatric and adult participants who received placebo combined.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Average Insulin Use in Units Per Kilogram Body Weight Per Day</title>
          <description>The need to use exogenous insulin is an indication that the body is not producing enough endogenous insulin. Higher amounts of insulin use indicate higher disease activity. Insulin use was collected each day for 5 days prior to the visit. Average insulin use per kg is the average insulin use over the 5 days prior to the visit divided by the participant's weight in kg.</description>
          <population>The modified intent to treat population includes all randomized participants who received any dose of assigned study treatment.</population>
          <units>Units per Kilogram Body Weight per Day</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="34"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="88"/>
                <count group_id="O6" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="54"/>
                    <count group_id="O2" value="25"/>
                    <count group_id="O3" value="33"/>
                    <count group_id="O4" value="19"/>
                    <count group_id="O5" value="87"/>
                    <count group_id="O6" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.139" lower_limit="0.09" upper_limit="0.19"/>
                    <measurement group_id="O2" value="0.126" lower_limit="0.05" upper_limit="0.20"/>
                    <measurement group_id="O3" value="0.015" lower_limit="-0.06" upper_limit="0.09"/>
                    <measurement group_id="O4" value="0.146" lower_limit="0.05" upper_limit="0.24"/>
                    <measurement group_id="O5" value="0.090" lower_limit="0.05" upper_limit="0.13"/>
                    <measurement group_id="O6" value="0.139" lower_limit="0.08" upper_limit="0.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="51"/>
                    <count group_id="O2" value="25"/>
                    <count group_id="O3" value="33"/>
                    <count group_id="O4" value="18"/>
                    <count group_id="O5" value="84"/>
                    <count group_id="O6" value="43"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.300" lower_limit="0.24" upper_limit="0.36"/>
                    <measurement group_id="O2" value="0.326" lower_limit="0.24" upper_limit="0.42"/>
                    <measurement group_id="O3" value="0.081" lower_limit="0.01" upper_limit="0.15"/>
                    <measurement group_id="O4" value="0.112" lower_limit="0.02" upper_limit="0.20"/>
                    <measurement group_id="O5" value="0.211" lower_limit="0.16" upper_limit="0.26"/>
                    <measurement group_id="O6" value="0.243" lower_limit="0.18" upper_limit="0.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="50"/>
                    <count group_id="O2" value="23"/>
                    <count group_id="O3" value="30"/>
                    <count group_id="O4" value="17"/>
                    <count group_id="O5" value="80"/>
                    <count group_id="O6" value="40"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.403" lower_limit="0.33" upper_limit="0.47"/>
                    <measurement group_id="O2" value="0.493" lower_limit="0.39" upper_limit="0.59"/>
                    <measurement group_id="O3" value="0.116" lower_limit="0.05" upper_limit="0.18"/>
                    <measurement group_id="O4" value="0.129" lower_limit="0.05" upper_limit="0.21"/>
                    <measurement group_id="O5" value="0.288" lower_limit="0.24" upper_limit="0.34"/>
                    <measurement group_id="O6" value="0.354" lower_limit="0.28" upper_limit="0.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 24</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.762</p_value>
            <p_value_desc>P-value comes from an analysis of covariance with outcome variable of change in average insulin use per kg from baseline and covariates of treatment, baseline average insulin use per kg, and age.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 52</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.640</p_value>
            <p_value_desc>P-value comes from an analysis of covariance with outcome variable of change in average insulin use per kg from baseline and covariates of treatment, baseline average insulin use per kg, and age.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 104</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.145</p_value>
            <p_value_desc>P-value comes from an analysis of covariance with outcome variable of change in avg insulin use per kg from baseline and covariates of treatment, baseline average insulin use per kg, and age.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 24</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.033</p_value>
            <p_value_desc>P-value comes from an analysis of covariance with outcome variable of change in average insulin use per kg from baseline and covariates of treatment, baseline average insulin use per kg, and age.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 52</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.591</p_value>
            <p_value_desc>P-value comes from an analysis of covariance with outcome variable of change in avg insulin use per kg from baseline and covariates of treatment, baseline avg insulin use per kg, and age.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 104</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.810</p_value>
            <p_value_desc>P-value comes from an analysis of covariance with outcome variable of change in average insulin use per kg from baseline and covariates of treatment, baseline average insulin use per kg, and age.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Week 24</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.178</p_value>
            <p_value_desc>P-value comes from an analysis of covariance with outcome variable of change in average insulin use per kg from baseline and covariates of treatment, baseline average insulin use per kg, and age.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Week 52</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.430</p_value>
            <p_value_desc>P-value comes from an analysis of covariance with outcome variable of change in average insulin use per kg from baseline and covariates of treatment, baseline average insulin use per kg, and age.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Week 104</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.149</p_value>
            <p_value_desc>P-value comes from an analysis of covariance with outcome variable of change in average insulin use per kg from baseline and covariates of treatment, baseline average insulin use per kg, and age.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Average Insulin Use Per Kg, Mixed Model</title>
        <description>The need to use exogenous insulin is an indication that the body is not producing enough endogenous insulin. Higher amounts of insulin use indicate higher disease activity. Insulin use was collected each day for 5 days prior to the visit. Average insulin use per kg is the average insulin use over the 5 days prior to the visit divided by the participant's weight in kg.</description>
        <time_frame>Baseline (Pre-treatment) to Weeks 12, 24, 39, 52, 78, and 104</time_frame>
        <population>The modified intent to treat population includes all randomized participants who received any dose of assigned study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Tocilizumab (TCZ) in Pediatric Participants</title>
            <description>Participants received intravenous (IV) infusions of either 8.0 mg/kg (body weight &gt;=30 kg) or 10.0 mg/kg (body weight &lt;30kg) tocilizumab every 4 weeks for 24 weeks. The dose was capped at 800 mg. Pediatric participants were 6 to 17 years old inclusive.</description>
          </group>
          <group group_id="O2">
            <title>Placebo in Pediatric Participants</title>
            <description>Participants received IV placebo infusions of saline of equal volume and appearance to the treatment. Pediatric participants were 6 to 17 years old inclusive.</description>
          </group>
          <group group_id="O3">
            <title>Tocilizumab (TCZ) in Adult Participants</title>
            <description>Participants received intravenous (IV) infusions of either 8.0 mg/kg (body weight &gt;=30 kg) or 10.0 mg/kg (body weight &lt;30kg) tocilizumab every 4 weeks for 24 weeks. The dose was capped at 800 mg. Adult participants were 18 to 45 years old inclusive.</description>
          </group>
          <group group_id="O4">
            <title>Placebo in Adult Participants</title>
            <description>Participants received IV placebo infusions of saline of equal volume and appearance to the treatment. Adult participants were 18 to 45 years old inclusive.</description>
          </group>
          <group group_id="O5">
            <title>Tocilizumab (TCZ) in Pooled Participants</title>
            <description>Participants received intravenous (IV) infusions of either 8.0 mg/kg (body weight &gt;=30 kg) or 10.0 mg/kg (body weight &lt;30kg) tocilizumab every 4 weeks for 24 weeks. The dose was capped at 800 mg. Pooled participants are the pediatric and adult participants who received TCZ combined.</description>
          </group>
          <group group_id="O6">
            <title>Placebo in Pooled Participants</title>
            <description>Participants received IV placebo infusions of saline of equal volume and appearance to the treatment. Pooled participants are the pediatric and adult participants who received placebo combined.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Average Insulin Use Per Kg, Mixed Model</title>
          <description>The need to use exogenous insulin is an indication that the body is not producing enough endogenous insulin. Higher amounts of insulin use indicate higher disease activity. Insulin use was collected each day for 5 days prior to the visit. Average insulin use per kg is the average insulin use over the 5 days prior to the visit divided by the participant's weight in kg.</description>
          <population>The modified intent to treat population includes all randomized participants who received any dose of assigned study treatment.</population>
          <units>Units per Kilogram Body Weight per Day</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="34"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="88"/>
                <count group_id="O6" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.45" lower_limit="0.40" upper_limit="0.51"/>
                    <measurement group_id="O2" value="0.45" lower_limit="0.37" upper_limit="0.53"/>
                    <measurement group_id="O3" value="0.29" lower_limit="0.22" upper_limit="0.35"/>
                    <measurement group_id="O4" value="0.37" lower_limit="0.29" upper_limit="0.46"/>
                    <measurement group_id="O5" value="0.39" lower_limit="0.35" upper_limit="0.43"/>
                    <measurement group_id="O6" value="0.42" lower_limit="0.36" upper_limit="0.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.50" lower_limit="0.45" upper_limit="0.56"/>
                    <measurement group_id="O2" value="0.51" lower_limit="0.44" upper_limit="0.59"/>
                    <measurement group_id="O3" value="0.31" lower_limit="0.24" upper_limit="0.37"/>
                    <measurement group_id="O4" value="0.40" lower_limit="0.31" upper_limit="0.48"/>
                    <measurement group_id="O5" value="0.43" lower_limit="0.38" upper_limit="0.47"/>
                    <measurement group_id="O6" value="0.47" lower_limit="0.41" upper_limit="0.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.57" lower_limit="0.51" upper_limit="0.62"/>
                    <measurement group_id="O2" value="0.59" lower_limit="0.52" upper_limit="0.67"/>
                    <measurement group_id="O3" value="0.33" lower_limit="0.26" upper_limit="0.40"/>
                    <measurement group_id="O4" value="0.43" lower_limit="0.34" upper_limit="0.52"/>
                    <measurement group_id="O5" value="0.47" lower_limit="0.43" upper_limit="0.52"/>
                    <measurement group_id="O6" value="0.53" lower_limit="0.47" upper_limit="0.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.62" lower_limit="0.57" upper_limit="0.68"/>
                    <measurement group_id="O2" value="0.66" lower_limit="0.58" upper_limit="0.74"/>
                    <measurement group_id="O3" value="0.35" lower_limit="0.27" upper_limit="0.43"/>
                    <measurement group_id="O4" value="0.46" lower_limit="0.36" upper_limit="0.56"/>
                    <measurement group_id="O5" value="0.51" lower_limit="0.47" upper_limit="0.56"/>
                    <measurement group_id="O6" value="0.58" lower_limit="0.52" upper_limit="0.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 78</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.73" lower_limit="0.67" upper_limit="0.79"/>
                    <measurement group_id="O2" value="0.80" lower_limit="0.71" upper_limit="0.89"/>
                    <measurement group_id="O3" value="0.39" lower_limit="0.30" upper_limit="0.49"/>
                    <measurement group_id="O4" value="0.51" lower_limit="0.39" upper_limit="0.64"/>
                    <measurement group_id="O5" value="0.60" lower_limit="0.54" upper_limit="0.65"/>
                    <measurement group_id="O6" value="0.68" lower_limit="0.61" upper_limit="0.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.84" lower_limit="0.77" upper_limit="0.91"/>
                    <measurement group_id="O2" value="0.94" lower_limit="0.83" upper_limit="1.04"/>
                    <measurement group_id="O3" value="0.43" lower_limit="0.32" upper_limit="0.55"/>
                    <measurement group_id="O4" value="0.57" lower_limit="0.42" upper_limit="0.72"/>
                    <measurement group_id="O5" value="0.68" lower_limit="0.62" upper_limit="0.74"/>
                    <measurement group_id="O6" value="0.79" lower_limit="0.70" upper_limit="0.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Screening to Week 104</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.103</p_value>
            <p_value_desc>P-value is for group difference in time trends from a longitudinal mixed effects model. Response variable was average insulin use per kg and covariates were treatment, study week, age, treatment*study week, age*study week.</p_value_desc>
            <method>Longitudinal mixed model</method>
            <method_desc>Random within-subject effects for intercept and study week were included assuming an unstructured covariance matrix.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Screening to Week 104</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.452</p_value>
            <p_value_desc>P-value is for group difference in time trends from a longitudinal mixed effects model. Response variable was average insulin use per kg and covariates were treatment, study week, age, treatment*study week, age*study week.</p_value_desc>
            <method>Longitudinal mixed model</method>
            <method_desc>Random within-subject effects for intercept and study week were included assuming an unstructured covariance matrix.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Screening to Week 104</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.091</p_value>
            <p_value_desc>P-value is for group difference in time trends from a longitudinal mixed effects model. Response variable was average insulin use per kg and covariates were treatment, study week, age, treatment*study week, age*study week.</p_value_desc>
            <method>Longitudinal mixed model</method>
            <method_desc>Random within-subject effects for intercept and study week were included assuming an unstructured covariance matrix.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Hemoglobin A1c</title>
        <description>Glycosylated hemoglobin (HbA1c) is a measure of the average plasma concentration of blood sugar (glucose) over the previous three months and measures the level of optimal management of underlying disease. An HbA1c of 5.6% or less is considered normal. HbA1c of 6.5% or higher is typical for individuals with Type 1 Diabetes mellitus (T1DM). The closer HbA1c levels are to normal, the better controlled the disease is.</description>
        <time_frame>Baseline (Pre-treatment) to Weeks 24, 52, and 104</time_frame>
        <population>The modified intent to treat population includes all randomized participants who received any dose of assigned study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Tocilizumab (TCZ) in Pediatric Participants</title>
            <description>Participants received intravenous (IV) infusions of either 8.0 mg/kg (body weight &gt;=30 kg) or 10.0 mg/kg (body weight &lt;30kg) tocilizumab every 4 weeks for 24 weeks. The dose was capped at 800 mg. Pediatric participants were 6 to 17 years old inclusive.</description>
          </group>
          <group group_id="O2">
            <title>Placebo in Pediatric Participants</title>
            <description>Participants received IV placebo infusions of saline of equal volume and appearance to the treatment. Pediatric participants were 6 to 17 years old inclusive.</description>
          </group>
          <group group_id="O3">
            <title>Tocilizumab (TCZ) in Adult Participants</title>
            <description>Participants received intravenous (IV) infusions of either 8.0 mg/kg (body weight &gt;=30 kg) or 10.0 mg/kg (body weight &lt;30kg) tocilizumab every 4 weeks for 24 weeks. The dose was capped at 800 mg. Adult participants were 18 to 45 years old inclusive.</description>
          </group>
          <group group_id="O4">
            <title>Placebo in Adult Participants</title>
            <description>Participants received IV placebo infusions of saline of equal volume and appearance to the treatment. Adult participants were 18 to 45 years old inclusive.</description>
          </group>
          <group group_id="O5">
            <title>Tocilizumab (TCZ) in Pooled Participants</title>
            <description>Participants received intravenous (IV) infusions of either 8.0 mg/kg (body weight &gt;=30 kg) or 10.0 mg/kg (body weight &lt;30kg) tocilizumab every 4 weeks for 24 weeks. The dose was capped at 800 mg. Pooled participants are the pediatric and adult participants who received TCZ combined.</description>
          </group>
          <group group_id="O6">
            <title>Placebo in Pooled Participants</title>
            <description>Participants received IV placebo infusions of saline of equal volume and appearance to the treatment. Pooled participants are the pediatric and adult participants who received placebo combined.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hemoglobin A1c</title>
          <description>Glycosylated hemoglobin (HbA1c) is a measure of the average plasma concentration of blood sugar (glucose) over the previous three months and measures the level of optimal management of underlying disease. An HbA1c of 5.6% or less is considered normal. HbA1c of 6.5% or higher is typical for individuals with Type 1 Diabetes mellitus (T1DM). The closer HbA1c levels are to normal, the better controlled the disease is.</description>
          <population>The modified intent to treat population includes all randomized participants who received any dose of assigned study treatment.</population>
          <units>percent (%)</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="34"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="88"/>
                <count group_id="O6" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="54"/>
                    <count group_id="O2" value="26"/>
                    <count group_id="O3" value="33"/>
                    <count group_id="O4" value="20"/>
                    <count group_id="O5" value="87"/>
                    <count group_id="O6" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.065" lower_limit="-0.17" upper_limit="0.30"/>
                    <measurement group_id="O2" value="0.368" lower_limit="0.02" upper_limit="0.71"/>
                    <measurement group_id="O3" value="-0.509" lower_limit="-0.80" upper_limit="-0.21"/>
                    <measurement group_id="O4" value="-0.136" lower_limit="-0.51" upper_limit="0.24"/>
                    <measurement group_id="O5" value="-0.163" lower_limit="-0.34" upper_limit="0.02"/>
                    <measurement group_id="O6" value="0.169" lower_limit="-0.08" upper_limit="0.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="25"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="20"/>
                    <count group_id="O5" value="85"/>
                    <count group_id="O6" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.650" lower_limit="0.24" upper_limit="1.06"/>
                    <measurement group_id="O2" value="1.134" lower_limit="0.53" upper_limit="1.74"/>
                    <measurement group_id="O3" value="0.152" lower_limit="-0.21" upper_limit="0.51"/>
                    <measurement group_id="O4" value="0.262" lower_limit="-0.19" upper_limit="0.72"/>
                    <measurement group_id="O5" value="0.459" lower_limit="0.16" upper_limit="0.76"/>
                    <measurement group_id="O6" value="0.753" lower_limit="0.34" upper_limit="1.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="49"/>
                    <count group_id="O2" value="22"/>
                    <count group_id="O3" value="31"/>
                    <count group_id="O4" value="19"/>
                    <count group_id="O5" value="80"/>
                    <count group_id="O6" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.734" lower_limit="0.33" upper_limit="1.14"/>
                    <measurement group_id="O2" value="1.042" lower_limit="0.44" upper_limit="1.64"/>
                    <measurement group_id="O3" value="0.253" lower_limit="-0.21" upper_limit="0.71"/>
                    <measurement group_id="O4" value="0.583" lower_limit="0.00" upper_limit="1.17"/>
                    <measurement group_id="O5" value="0.556" lower_limit="0.25" upper_limit="0.86"/>
                    <measurement group_id="O6" value="0.812" lower_limit="0.38" upper_limit="1.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 24</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.154</p_value>
            <p_value_desc>P-value comes from an analysis of covariance with outcome variable of change in HbA1c from baseline and covariates of treatment, baseline HbA1c, and age.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 52</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.193</p_value>
            <p_value_desc>P-value comes from an analysis of covariance with outcome variable of change in HbA1c from baseline and covariates of treatment, baseline HbA1c, and age.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 104</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.397</p_value>
            <p_value_desc>P-value comes from an analysis of covariance with outcome variable of change in HbA1c from baseline and covariates of treatment, baseline HbA1c, and age.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 24</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.125</p_value>
            <p_value_desc>P-value comes from an analysis of covariance with outcome variable of change in HbA1c from baseline and covariates of treatment, baseline HbA1c, and age.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 52</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.705</p_value>
            <p_value_desc>P-value comes from an analysis of covariance with outcome variable of change in HbA1c from baseline and covariates of treatment, baseline HbA1c, and age.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Week 104</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.378</p_value>
            <p_value_desc>P-value comes from an analysis of covariance with outcome variable of change in HbA1c from baseline and covariates of treatment, baseline HbA1c, and age.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Week 24</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.035</p_value>
            <p_value_desc>P-value comes from an analysis of covariance with outcome variable of change in HbA1c from baseline and covariates of treatment, baseline HbA1c, and age.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Week 52</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.262</p_value>
            <p_value_desc>P-value comes from an analysis of covariance with outcome variable of change in HbA1c from baseline and covariates of treatment, baseline HbA1c, and age.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Week 104</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.338</p_value>
            <p_value_desc>P-value comes from an analysis of covariance with outcome variable of change in HbA1c from baseline and covariates of treatment, baseline HbA1c, and age.</p_value_desc>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Hemoglobin A1C (HbA1c) Level in Participants, Mixed Model</title>
        <description>Glycosylated hemoglobin (HbA1c) is a measure of the average plasma concentration of blood sugar (glucose) over the previous three months and measures the level of optimal management of underlying disease. An HbA1c of 5.6% or less is considered normal. HbA1c of 6.5% or higher is typical for individuals with Type 1 Diabetes mellitus (T1DM). The closer HbA1c levels are to normal, the better controlled the disease is.</description>
        <time_frame>Baseline (Pre-treatment) to Weeks 12, 24, 39, 52, 78, and 104</time_frame>
        <population>The modified intent to treat population includes all randomized participants who received any dose of assigned study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Tocilizumab (TCZ) in Pediatric Participants</title>
            <description>Participants received intravenous (IV) infusions of either 8.0 mg/kg (body weight &gt;=30 kg) or 10.0 mg/kg (body weight &lt;30kg) tocilizumab every 4 weeks for 24 weeks. The dose was capped at 800 mg. Pediatric participants were 6 to 17 years old inclusive.</description>
          </group>
          <group group_id="O2">
            <title>Placebo in Pediatric Participants</title>
            <description>Participants received IV placebo infusions of saline of equal volume and appearance to the treatment. Pediatric participants were 6 to 17 years old inclusive.</description>
          </group>
          <group group_id="O3">
            <title>Tocilizumab (TCZ) in Adult Participants</title>
            <description>Participants received intravenous (IV) infusions of either 8.0 mg/kg (body weight &gt;=30 kg) or 10.0 mg/kg (body weight &lt;30kg) tocilizumab every 4 weeks for 24 weeks. The dose was capped at 800 mg. Adult participants were 18 to 45 years old inclusive.</description>
          </group>
          <group group_id="O4">
            <title>Placebo in Adult Participants</title>
            <description>Participants received IV placebo infusions of saline of equal volume and appearance to the treatment. Adult participants were 18 to 45 years old inclusive.</description>
          </group>
          <group group_id="O5">
            <title>Tocilizumab (TCZ) in Pooled Participants</title>
            <description>Participants received intravenous (IV) infusions of either 8.0 mg/kg (body weight &gt;=30 kg) or 10.0 mg/kg (body weight &lt;30kg) tocilizumab every 4 weeks for 24 weeks. The dose was capped at 800 mg. Pooled participants are the pediatric and adult participants who received TCZ combined.</description>
          </group>
          <group group_id="O6">
            <title>Placebo in Pooled Participants</title>
            <description>Participants received IV placebo infusions of saline of equal volume and appearance to the treatment. Pooled participants are the pediatric and adult participants who received placebo combined.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Hemoglobin A1C (HbA1c) Level in Participants, Mixed Model</title>
          <description>Glycosylated hemoglobin (HbA1c) is a measure of the average plasma concentration of blood sugar (glucose) over the previous three months and measures the level of optimal management of underlying disease. An HbA1c of 5.6% or less is considered normal. HbA1c of 6.5% or higher is typical for individuals with Type 1 Diabetes mellitus (T1DM). The closer HbA1c levels are to normal, the better controlled the disease is.</description>
          <population>The modified intent to treat population includes all randomized participants who received any dose of assigned study treatment.</population>
          <units>percent (%)</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="34"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="88"/>
                <count group_id="O6" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.74" lower_limit="6.50" upper_limit="6.97"/>
                    <measurement group_id="O2" value="6.99" lower_limit="6.65" upper_limit="7.32"/>
                    <measurement group_id="O3" value="5.88" lower_limit="5.59" upper_limit="6.18"/>
                    <measurement group_id="O4" value="6.04" lower_limit="5.65" upper_limit="6.43"/>
                    <measurement group_id="O5" value="6.40" lower_limit="6.21" upper_limit="6.58"/>
                    <measurement group_id="O6" value="6.60" lower_limit="6.35" upper_limit="6.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.87" lower_limit="6.65" upper_limit="7.10"/>
                    <measurement group_id="O2" value="7.20" lower_limit="6.88" upper_limit="7.52"/>
                    <measurement group_id="O3" value="6.02" lower_limit="5.71" upper_limit="6.34"/>
                    <measurement group_id="O4" value="6.19" lower_limit="5.78" upper_limit="6.60"/>
                    <measurement group_id="O5" value="6.54" lower_limit="6.35" upper_limit="6.72"/>
                    <measurement group_id="O6" value="6.79" lower_limit="6.54" upper_limit="7.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 39</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.05" lower_limit="6.80" upper_limit="7.29"/>
                    <measurement group_id="O2" value="7.46" lower_limit="7.11" upper_limit="7.82"/>
                    <measurement group_id="O3" value="6.19" lower_limit="5.85" upper_limit="6.54"/>
                    <measurement group_id="O4" value="6.38" lower_limit="5.93" upper_limit="6.83"/>
                    <measurement group_id="O5" value="6.71" lower_limit="6.51" upper_limit="6.91"/>
                    <measurement group_id="O6" value="7.02" lower_limit="6.75" upper_limit="7.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.20" lower_limit="6.91" upper_limit="7.48"/>
                    <measurement group_id="O2" value="7.69" lower_limit="7.28" upper_limit="8.11"/>
                    <measurement group_id="O3" value="6.34" lower_limit="5.96" upper_limit="6.73"/>
                    <measurement group_id="O4" value="6.54" lower_limit="6.04" upper_limit="7.03"/>
                    <measurement group_id="O5" value="6.86" lower_limit="6.63" upper_limit="7.09"/>
                    <measurement group_id="O6" value="7.23" lower_limit="6.91" upper_limit="7.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 78</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.50" lower_limit="7.10" upper_limit="7.90"/>
                    <measurement group_id="O2" value="8.16" lower_limit="7.57" upper_limit="8.74"/>
                    <measurement group_id="O3" value="6.64" lower_limit="6.17" upper_limit="7.11"/>
                    <measurement group_id="O4" value="6.86" lower_limit="6.26" upper_limit="7.47"/>
                    <measurement group_id="O5" value="7.16" lower_limit="6.85" upper_limit="7.46"/>
                    <measurement group_id="O6" value="7.63" lower_limit="7.21" upper_limit="8.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.80" lower_limit="7.26" upper_limit="8.34"/>
                    <measurement group_id="O2" value="8.62" lower_limit="7.83" upper_limit="9.40"/>
                    <measurement group_id="O3" value="6.94" lower_limit="6.37" upper_limit="7.51"/>
                    <measurement group_id="O4" value="7.19" lower_limit="6.45" upper_limit="7.92"/>
                    <measurement group_id="O5" value="7.45" lower_limit="7.06" upper_limit="7.85"/>
                    <measurement group_id="O6" value="8.04" lower_limit="7.49" upper_limit="8.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Screening to Week 104</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.493</p_value>
            <p_value_desc>P-value is for group difference in time trends from a longitudinal mixed effects model. Response variable was HbA1c and covariates were treatment, study week, spline week (at week 4), age, treatment*spline week, treatment*study week, age*study week.</p_value_desc>
            <method>Longitudinal mixed model</method>
            <method_desc>Random within-subject effects for intercept, study week, and spline week were included assuming an unstructured covariance matrix.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Screening to Week 104</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.659</p_value>
            <p_value_desc>P-value is for group difference in time trends from a longitudinal mixed effects model. Response variable was HbA1c and covariates were treatment, study week, spline week (at week 4), age, treatment*spline week, treatment*study week, age*study week.</p_value_desc>
            <method>Longitudinal mixed model</method>
            <method_desc>Random within-subject effects for intercept, study week, and spline week were included assuming an unstructured covariance matrix.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Screening to Week 104</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.407</p_value>
            <p_value_desc>P-value is for group difference in time trends from a longitudinal mixed effects model. Response variable was HbA1c and covariates were treatment, study week, spline week (at week 4), age, treatment*spline week, treatment*study week, age*study week.</p_value_desc>
            <method>Longitudinal mixed model</method>
            <method_desc>Random within-subject effects for intercept, study week, and spline week were included assuming an unstructured covariance matrix.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Experienced at Least One Major Hypoglycemic Event After Treatment Initiation</title>
        <description>Major hypoglycemic adverse events are defined as: Blood glucose concentration &lt; 40 mg/dL (Grades 3-5, NCI-CTCAE version 4.03*), or hypoglycemic events involving seizure or loss of consciousness (coma) or requiring assistance from another individual in order to recover.&#xD;
*NCI-CTCAE: National Cancer Institute Common Terminology Criteria for Adverse Events</description>
        <time_frame>Day 0 (Treatment Initiation) to Weeks 52 and 104</time_frame>
        <population>The safety population includes all participants who received any degree of study treatment. Safety analyses are based on actual treatment the participants receive.</population>
        <group_list>
          <group group_id="O1">
            <title>Tocilizumab (TCZ) in Pediatric Participants</title>
            <description>Participants received intravenous (IV) infusions of either 8.0 mg/kg (body weight &gt;=30 kg) or 10.0 mg/kg (body weight &lt;30kg) tocilizumab every 4 weeks for 24 weeks. The dose was capped at 800 mg. Pediatric participants were 6 to 17 years old inclusive.</description>
          </group>
          <group group_id="O2">
            <title>Placebo in Pediatric Participants</title>
            <description>Participants received IV placebo infusions of saline of equal volume and appearance to the treatment. Pediatric participants were 6 to 17 years old inclusive.</description>
          </group>
          <group group_id="O3">
            <title>Tocilizumab (TCZ) in Adult Participants</title>
            <description>Participants received intravenous (IV) infusions of either 8.0 mg/kg (body weight &gt;=30 kg) or 10.0 mg/kg (body weight &lt;30kg) tocilizumab every 4 weeks for 24 weeks. The dose was capped at 800 mg. Adult participants were 18 to 45 years old inclusive.</description>
          </group>
          <group group_id="O4">
            <title>Placebo in Adult Participants</title>
            <description>Participants received IV placebo infusions of saline of equal volume and appearance to the treatment. Adult participants were 18 to 45 years old inclusive.</description>
          </group>
          <group group_id="O5">
            <title>Tocilizumab (TCZ) in Pooled Participants</title>
            <description>Participants received intravenous (IV) infusions of either 8.0 mg/kg (body weight &gt;=30 kg) or 10.0 mg/kg (body weight &lt;30kg) tocilizumab every 4 weeks for 24 weeks. The dose was capped at 800 mg. Pooled participants are the pediatric and adult participants who received TCZ combined.</description>
          </group>
          <group group_id="O6">
            <title>Placebo in Pooled Participants</title>
            <description>Participants received IV placebo infusions of saline of equal volume and appearance to the treatment. Pooled participants are the pediatric and adult participants who received placebo combined.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Experienced at Least One Major Hypoglycemic Event After Treatment Initiation</title>
          <description>Major hypoglycemic adverse events are defined as: Blood glucose concentration &lt; 40 mg/dL (Grades 3-5, NCI-CTCAE version 4.03*), or hypoglycemic events involving seizure or loss of consciousness (coma) or requiring assistance from another individual in order to recover.&#xD;
*NCI-CTCAE: National Cancer Institute Common Terminology Criteria for Adverse Events</description>
          <population>The safety population includes all participants who received any degree of study treatment. Safety analyses are based on actual treatment the participants receive.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="34"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="88"/>
                <count group_id="O6" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0 to Week 52</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="29"/>
                    <measurement group_id="O6" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 0 to Week 104</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="43"/>
                    <measurement group_id="O6" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to Week 52</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.634</p_value>
            <p_value_desc>P-value is from comparing the number of participants with a hypoglycemic event between the two treatment groups using Fisher's exact test.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Baseline to Week 104/End of Study</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>1.000</p_value>
            <p_value_desc>P-value is from comparing the number of participants with a hypoglycemic event between the two treatment groups using Fisher's exact test.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Baseline to Week 52</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.329</p_value>
            <p_value_desc>P-value is from comparing the number of participants with a hypoglycemic event between the two treatment groups using Fisher's exact test.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Baseline to Week 104/End of Study</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>1.000</p_value>
            <p_value_desc>P-value is from comparing the number of participants with a hypoglycemic event between the two treatment groups using Fisher's exact test.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Baseline to Week 52</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.847</p_value>
            <p_value_desc>P-value is from comparing the number of participants with a hypoglycemic event between the two treatment groups using Fisher's exact test.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Baseline to Week 104/End of Study</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.858</p_value>
            <p_value_desc>P-value is from comparing the number of participants with a hypoglycemic event between the two treatment groups using Fisher's exact test.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Experienced Infusion-Related Adverse Events</title>
        <description>An infusion/dose reaction is defined as an adverse event occurring during and within 24 hours after the infusion or subcutaneous injection of tocilizumab. This may include hypersensitivity reactions or anaphylactic reactions.</description>
        <time_frame>Day 0 (Treatment Initiation) to Week 52</time_frame>
        <population>The safety population includes all participants who received any degree of study treatment. Safety analyses are based on actual treatment the participants receive.</population>
        <group_list>
          <group group_id="O1">
            <title>Tocilizumab (TCZ) in Pediatric Participants</title>
            <description>Participants received intravenous (IV) infusions of either 8.0 mg/kg (body weight &gt;=30 kg) or 10.0 mg/kg (body weight &lt;30kg) tocilizumab every 4 weeks for 24 weeks. The dose was capped at 800 mg. Pediatric participants were 6 to 17 years old inclusive.</description>
          </group>
          <group group_id="O2">
            <title>Placebo in Pediatric Participants</title>
            <description>Participants received IV placebo infusions of saline of equal volume and appearance to the treatment. Pediatric participants were 6 to 17 years old inclusive.</description>
          </group>
          <group group_id="O3">
            <title>Tocilizumab (TCZ) in Adult Participants</title>
            <description>Participants received intravenous (IV) infusions of either 8.0 mg/kg (body weight &gt;=30 kg) or 10.0 mg/kg (body weight &lt;30kg) tocilizumab every 4 weeks for 24 weeks. The dose was capped at 800 mg. Adult participants were 18 to 45 years old inclusive.</description>
          </group>
          <group group_id="O4">
            <title>Placebo in Adult Participants</title>
            <description>Participants received IV placebo infusions of saline of equal volume and appearance to the treatment. Adult participants were 18 to 45 years old inclusive.</description>
          </group>
          <group group_id="O5">
            <title>Tocilizumab (TCZ) in Pooled Participants</title>
            <description>Participants received intravenous (IV) infusions of either 8.0 mg/kg (body weight &gt;=30 kg) or 10.0 mg/kg (body weight &lt;30kg) tocilizumab every 4 weeks for 24 weeks. The dose was capped at 800 mg. Pooled participants are the pediatric and adult participants who received TCZ combined.</description>
          </group>
          <group group_id="O6">
            <title>Placebo in Pooled Participants</title>
            <description>Participants received IV placebo infusions of saline of equal volume and appearance to the treatment. Pooled participants are the pediatric and adult participants who received placebo combined.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Experienced Infusion-Related Adverse Events</title>
          <description>An infusion/dose reaction is defined as an adverse event occurring during and within 24 hours after the infusion or subcutaneous injection of tocilizumab. This may include hypersensitivity reactions or anaphylactic reactions.</description>
          <population>The safety population includes all participants who received any degree of study treatment. Safety analyses are based on actual treatment the participants receive.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="34"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="88"/>
                <count group_id="O6" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="9"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Treatment start to Week 52</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.296</p_value>
            <p_value_desc>P-value is from comparing the number of participants with the AEs of interest between the two treatment groups using Fisher's exact test.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Treatment start to Week 52</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.145</p_value>
            <p_value_desc>P-value is from comparing the number of participants with the AEs of interest between the two treatment groups using Fisher's exact test.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Treatment start to Week 52</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.027</p_value>
            <p_value_desc>P-value is from comparing the number of participants with the AEs of interest between the two treatment groups using Fisher's exact test.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Experienced Hypersensitivity Adverse Events</title>
        <description>Signs of a possible hypersensitivity reaction to the study drug include but are not limited to:&#xD;
Fever, chills, pruritus, urticaria, angioedema, and skin rash&#xD;
Cardiopulmonary reactions, including chest pain, dyspnea, hypotension or hypertension</description>
        <time_frame>Day 0 (Treatment Initiation) to Week 52</time_frame>
        <population>The safety population includes all participants who received any degree of study treatment. Safety analyses are based on actual treatment the participants receive.</population>
        <group_list>
          <group group_id="O1">
            <title>Tocilizumab (TCZ) in Pediatric Participants</title>
            <description>Participants received intravenous (IV) infusions of either 8.0 mg/kg (body weight &gt;=30 kg) or 10.0 mg/kg (body weight &lt;30kg) tocilizumab every 4 weeks for 24 weeks. The dose was capped at 800 mg. Pediatric participants were 6 to 17 years old inclusive.</description>
          </group>
          <group group_id="O2">
            <title>Placebo in Pediatric Participants</title>
            <description>Participants received IV placebo infusions of saline of equal volume and appearance to the treatment. Pediatric participants were 6 to 17 years old inclusive.</description>
          </group>
          <group group_id="O3">
            <title>Tocilizumab (TCZ) in Adult Participants</title>
            <description>Participants received intravenous (IV) infusions of either 8.0 mg/kg (body weight &gt;=30 kg) or 10.0 mg/kg (body weight &lt;30kg) tocilizumab every 4 weeks for 24 weeks. The dose was capped at 800 mg. Adult participants were 18 to 45 years old inclusive.</description>
          </group>
          <group group_id="O4">
            <title>Placebo in Adult Participants</title>
            <description>Participants received IV placebo infusions of saline of equal volume and appearance to the treatment. Adult participants were 18 to 45 years old inclusive.</description>
          </group>
          <group group_id="O5">
            <title>Tocilizumab (TCZ) in Pooled Participants</title>
            <description>Participants received intravenous (IV) infusions of either 8.0 mg/kg (body weight &gt;=30 kg) or 10.0 mg/kg (body weight &lt;30kg) tocilizumab every 4 weeks for 24 weeks. The dose was capped at 800 mg. Pooled participants are the pediatric and adult participants who received TCZ combined.</description>
          </group>
          <group group_id="O6">
            <title>Placebo in Pooled Participants</title>
            <description>Participants received IV placebo infusions of saline of equal volume and appearance to the treatment. Pooled participants are the pediatric and adult participants who received placebo combined.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Experienced Hypersensitivity Adverse Events</title>
          <description>Signs of a possible hypersensitivity reaction to the study drug include but are not limited to:&#xD;
Fever, chills, pruritus, urticaria, angioedema, and skin rash&#xD;
Cardiopulmonary reactions, including chest pain, dyspnea, hypotension or hypertension</description>
          <population>The safety population includes all participants who received any degree of study treatment. Safety analyses are based on actual treatment the participants receive.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="34"/>
                <count group_id="O4" value="20"/>
                <count group_id="O5" value="88"/>
                <count group_id="O6" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Treatment start to Week 52</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.547</p_value>
            <p_value_desc>P-value is from comparing the number of participants with the AEs of interest between the two treatment groups using Fisher's exact test.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Treatment start to Week 52</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.551</p_value>
            <p_value_desc>P-value is from comparing the number of participants with the AEs of interest between the two treatment groups using Fisher's exact test.</p_value_desc>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 104 weeks.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Tocilizumab (TCZ) in Pediatric Participants</title>
          <description>Participants received intravenous (IV) infusions of either 8.0 mg/kg (body weight &gt;=30 kg) or 10.0 mg/kg (body weight &lt;30kg) tocilizumab every 4 weeks for 24 weeks. The dose was capped at 800 mg. Pediatric participants were 6 to 17 years old inclusive.</description>
        </group>
        <group group_id="E2">
          <title>Placebo in Pediatric Participants</title>
          <description>Participants received IV placebo infusions of saline of equal volume and appearance to the treatment. Pediatric participants were 6 to 17 years old inclusive.</description>
        </group>
        <group group_id="E3">
          <title>Tocilizumab (TCZ) in Adult Participants</title>
          <description>Participants received intravenous (IV) infusions of either 8.0 mg/kg (body weight &gt;=30 kg) or 10.0 mg/kg (body weight &lt;30kg) tocilizumab every 4 weeks for 24 weeks. The dose was capped at 800 mg. Adult participants were 18 to 45 years old inclusive.</description>
        </group>
        <group group_id="E4">
          <title>Placebo in Adult Participants</title>
          <description>Participants received IV placebo infusions of saline of equal volume and appearance to the treatment. Adult participants were 18 to 45 years old inclusive.</description>
        </group>
        <group group_id="E5">
          <title>Tocilizumab (TCZ) in Pooled Participants</title>
          <description>Participants received intravenous (IV) infusions of either 8.0 mg/kg (body weight &gt;=30 kg) or 10.0 mg/kg (body weight &lt;30kg) tocilizumab every 4 weeks for 24 weeks. The dose was capped at 800 mg. Pooled participants are the pediatric and adult participants who received TCZ combined.</description>
        </group>
        <group group_id="E6">
          <title>Placebo in Pooled Participants</title>
          <description>Participants received IV placebo infusions of saline of equal volume and appearance to the treatment. Pooled participants are the pediatric and adult participants who received placebo combined.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>17.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="88"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Vaccination site reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Infectious mononucleosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Forearm fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Thoracic outlet syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Sleep apnoea syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>17.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="54"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="31" subjects_at_risk="34"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="20"/>
                <counts group_id="E5" subjects_affected="83" subjects_at_risk="88"/>
                <counts group_id="E6" subjects_affected="45" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="88"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Splenomegaly</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Basedow's disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye irritation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="88"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E5" events="3" subjects_affected="2" subjects_at_risk="88"/>
                <counts group_id="E6" events="5" subjects_affected="4" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="54"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" events="9" subjects_affected="7" subjects_at_risk="88"/>
                <counts group_id="E6" events="4" subjects_affected="3" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="27"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="88"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Dental caries</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="88"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="54"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="34"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E5" events="9" subjects_affected="8" subjects_at_risk="88"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="27"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="88"/>
                <counts group_id="E6" events="7" subjects_affected="6" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Food poisoning</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" events="4" subjects_affected="3" subjects_at_risk="88"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="88"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="20" subjects_affected="13" subjects_at_risk="54"/>
                <counts group_id="E2" events="11" subjects_affected="4" subjects_at_risk="27"/>
                <counts group_id="E3" events="8" subjects_affected="5" subjects_at_risk="34"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E5" events="28" subjects_affected="18" subjects_at_risk="88"/>
                <counts group_id="E6" events="13" subjects_affected="6" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="16" subjects_affected="10" subjects_at_risk="54"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="27"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="34"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E5" events="20" subjects_affected="14" subjects_at_risk="88"/>
                <counts group_id="E6" events="8" subjects_affected="7" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Adverse drug reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E5" events="4" subjects_affected="3" subjects_at_risk="88"/>
                <counts group_id="E6" events="7" subjects_affected="5" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="54"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="27"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" events="10" subjects_affected="8" subjects_at_risk="88"/>
                <counts group_id="E6" events="5" subjects_affected="4" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Temperature intolerance</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="54"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E5" events="7" subjects_affected="6" subjects_at_risk="88"/>
                <counts group_id="E6" events="5" subjects_affected="4" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="88"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="54"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="88"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Epstein-Barr virus infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="88"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="54"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="34"/>
                <counts group_id="E4" events="6" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E5" events="15" subjects_affected="15" subjects_at_risk="88"/>
                <counts group_id="E6" events="9" subjects_affected="5" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E5" events="5" subjects_affected="4" subjects_at_risk="88"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="54"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="27"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E5" events="9" subjects_affected="9" subjects_at_risk="88"/>
                <counts group_id="E6" events="7" subjects_affected="7" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="10" subjects_affected="7" subjects_at_risk="54"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="27"/>
                <counts group_id="E3" events="10" subjects_affected="5" subjects_at_risk="34"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E5" events="20" subjects_affected="12" subjects_at_risk="88"/>
                <counts group_id="E6" events="8" subjects_affected="6" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" events="4" subjects_affected="3" subjects_at_risk="88"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Otitis externa</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="88"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E5" events="4" subjects_affected="3" subjects_at_risk="88"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="54"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="34"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" events="10" subjects_affected="9" subjects_at_risk="88"/>
                <counts group_id="E6" events="4" subjects_affected="3" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Pharyngitis streptococcal</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="54"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E5" events="6" subjects_affected="6" subjects_at_risk="88"/>
                <counts group_id="E6" events="2" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Pneumonia mycoplasmal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="88"/>
                <counts group_id="E6" events="3" subjects_affected="2" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="11" subjects_affected="5" subjects_at_risk="54"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="34"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" events="15" subjects_affected="9" subjects_at_risk="88"/>
                <counts group_id="E6" events="3" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="88"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="82" subjects_affected="26" subjects_at_risk="54"/>
                <counts group_id="E2" events="35" subjects_affected="13" subjects_at_risk="27"/>
                <counts group_id="E3" events="42" subjects_affected="15" subjects_at_risk="34"/>
                <counts group_id="E4" events="30" subjects_affected="12" subjects_at_risk="20"/>
                <counts group_id="E5" events="124" subjects_affected="41" subjects_at_risk="88"/>
                <counts group_id="E6" events="65" subjects_affected="25" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E3" events="6" subjects_affected="5" subjects_at_risk="34"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E5" events="6" subjects_affected="5" subjects_at_risk="88"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Vulvovaginal mycotic infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="88"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="88"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="88"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" events="7" subjects_affected="4" subjects_at_risk="88"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Sunburn</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Traumatic haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Body mass index increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="5" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" events="7" subjects_affected="5" subjects_at_risk="88"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="88"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="85" subjects_affected="28" subjects_at_risk="54"/>
                <counts group_id="E2" events="47" subjects_affected="14" subjects_at_risk="27"/>
                <counts group_id="E3" events="42" subjects_affected="15" subjects_at_risk="34"/>
                <counts group_id="E4" events="11" subjects_affected="7" subjects_at_risk="20"/>
                <counts group_id="E5" events="127" subjects_affected="43" subjects_at_risk="88"/>
                <counts group_id="E6" events="58" subjects_affected="21" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Hypophosphataemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="34"/>
                <counts group_id="E4" events="8" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E5" events="8" subjects_affected="7" subjects_at_risk="88"/>
                <counts group_id="E6" events="8" subjects_affected="4" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="34"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="88"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="88"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="54"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="34"/>
                <counts group_id="E4" events="5" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E5" events="7" subjects_affected="7" subjects_at_risk="88"/>
                <counts group_id="E6" events="7" subjects_affected="3" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" events="4" subjects_affected="3" subjects_at_risk="88"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E5" events="5" subjects_affected="4" subjects_at_risk="88"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Synovial cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Temporomandibular joint syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Tendonitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="88"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Benign neoplasm of skin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Skin papilloma</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="88"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="34"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E5" events="6" subjects_affected="6" subjects_at_risk="88"/>
                <counts group_id="E6" events="5" subjects_affected="3" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Dizziness postural</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="24" subjects_affected="14" subjects_at_risk="54"/>
                <counts group_id="E2" events="17" subjects_affected="6" subjects_at_risk="27"/>
                <counts group_id="E3" events="8" subjects_affected="5" subjects_at_risk="34"/>
                <counts group_id="E4" events="7" subjects_affected="6" subjects_at_risk="20"/>
                <counts group_id="E5" events="32" subjects_affected="19" subjects_at_risk="88"/>
                <counts group_id="E6" events="24" subjects_affected="12" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="88"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="88"/>
                <counts group_id="E6" events="5" subjects_affected="4" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="34"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="88"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Stress</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="54"/>
                <counts group_id="E2" events="9" subjects_affected="7" subjects_at_risk="27"/>
                <counts group_id="E3" events="4" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E5" events="13" subjects_affected="11" subjects_at_risk="88"/>
                <counts group_id="E6" events="11" subjects_affected="9" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="54"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="34"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E5" events="10" subjects_affected="8" subjects_at_risk="88"/>
                <counts group_id="E6" events="5" subjects_affected="5" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="17" subjects_affected="9" subjects_at_risk="54"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="27"/>
                <counts group_id="E3" events="6" subjects_affected="5" subjects_at_risk="34"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E5" events="23" subjects_affected="14" subjects_at_risk="88"/>
                <counts group_id="E6" events="6" subjects_affected="5" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Tonsillolith</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="8" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" events="8" subjects_affected="2" subjects_at_risk="88"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Dermal cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" events="5" subjects_affected="3" subjects_at_risk="88"/>
                <counts group_id="E6" events="2" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="88"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="88"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="88"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Ingrowing nail</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="88"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Lipohypertrophy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="27"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="88"/>
                <counts group_id="E6" events="6" subjects_affected="5" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Papule</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="54"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="34"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E5" events="13" subjects_affected="12" subjects_at_risk="88"/>
                <counts group_id="E6" events="6" subjects_affected="5" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Rash pruritic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="88"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Skin fissures</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Skin mass</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Family stress</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="88"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Director, Clinical Research Operations Program</name_or_title>
      <organization>DAIT/NIAID</organization>
      <phone>301-594-7669</phone>
      <email>DAITClinicalTrialsGov@niaid.nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

